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Abstract 
RNAi (RNA interference) is emerging as a promising tool for cancer therapy. Small 
interfering RNA (siRNA) molecules are activated in that pathway to reduce specific tumour 
cell RNAs that mediate malignancy. SiRNA treatment has been primarily limited to in vitro 
studies: lack of efficient, preferential in vivo delivery to target cells remains a major obstacle. 
Many human tumours overexpress folate receptors (FR), and siRNA-mediated reduction of 
thymidylate synthase (TS) sensitizes tumour cells to anti-TS drugs. I developed a folate-
containing cationic liposome to preferentially deliver anti-TS siRNA to FR-expressing 
human tumour cells. I show, in vitro, that liposome-encapsulated siRNA (but not free 
siRNA) is delivered to human tumour cells, and that FR-targeting liposomes preferentially 
deliver siRNA into FR-positive human tumour cells. However, liposome-delivered siRNA 
did not reduce TS mRNA, an obstacle that must be overcome before the advantage of 
preferential siRNA delivery can be realized in vivo. 
Keywords 
Cationic liposomes, folate receptor, cancer, small interfering RNA (siRNA), RNA 
interference, thymidylate synthase  
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Chapter 1  
1 Introduction 
Preamble  
 The purpose of this introduction section will be to establish the basic principles 
encompassing antisense therapy with emphasis placed on the delivery challenges limiting 
their effective application in an in vivo setting. Initially, I will give a brief overview on 
the history (Section 1.1) and mechanism (Section 1.2) of the RNA interference (RNAi) 
pathway and its exploitation in disease treatment (Section 1.3). Emphasis will be placed 
on RNAi effector molecules: small interfering RNAs (siRNAs) and their application(s) in 
cancer therapeutics (Section 1.4) and specifically targeting thymidylate synthase (TS), an 
enzyme recognized as mediating malignant characteristics and well-established as a 
target of multiple anticancer drugs (Section 1.5). I will then discuss the inherent 
challenges to antisense delivery (Section 1.6), referencing several common delivery 
strategies (Section 1.7.1-1.7.2) before focusing on the use of liposomes as they pertain to 
this project (Section 1.7.3). Finally, I will talk about the use of targeting moieties to 
enhance liposome-antisense delivery (Section 1.8) and specifically the benefits and 
challenges of decorating liposomes with folate to exploit the folate receptor on cancer 
cells (Section 1.9). 
1.1 Discovery and history of RNA interference  
 The discovery of the RNA interference pathway is the culmination of the  work of 
many scientific groups. In an attempt to circumvent problems inherent in classical genetic 
analysis using mutant variants, Izant and Weintraub investigated the ability of expression 
vectors directing production of antisense RNA (i.e., RNA complementary to mRNA 
encoding information essential for production of protein) to inhibit thymidine kinase 
(TK) gene activity in eukaryotic cells. They discovered a 4-fold reduction of transient TK 
expression in TK
-
 mouse L cells micro-injected with expression vectors containing DNA 
directing production of TK mRNA and, coincidentally, RNA antisense to TK mRNA, 
compared to control cells injected with the same TK mRNA expression vector but a 
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second vector producing control RNA that was not complementary to TK mRNA
1
. 
Similarly, Fire and colleagues reported that DNA fragments inserted into expression 
vectors in reverse orientation could produce antisense RNA molecules that interfered 
with gene expression in Caenorhabditis elegans
2
. In plants, posttranscriptional gene 
silencing was achieved through nucleic acids of either foreign or endogenous origin, 
where a reduction of RNA molecules similar in sequence to introduced DNA was 
observed
3,4
. Then in 1998, a significant advancement took place in the field of RNAi 
when Fire and Mello reported that the introduction of only a few strands of double-
stranded RNA could cause potent and specific gene inhibition in C. elegans
5
. The finding 
of the causative agent for this phenomenon, which they called RNAi, earned them a 
Nobel Prize in Physiology or Medicine in 2006. 
1.2 Mechanism of action of RNAi 
 Although genomic sequencing may reveal more in the future, there are currently 
three major classes of small regulatory RNAs that have been recognized as naturally-
occurring antisense molecules: short interfering RNAs (siRNAs), microRNAs (miRNAs) 
and PIWI-Interacting RNAs (piRNAs) (Figure 1.1). For the purposes of this thesis, only 
siRNAs will be discussed in detail (all three classes involved in RNAi are reviewed in 
detail by Jinek and Doudna
6
). SiRNA molecules are typically characterized as being 
approximately 20-30 nucleotides in length
7
 and are generated from longer double-
stranded RNA precursors that are processed by Dicer, a evolutionary conserved enzyme 
from the RNase III family of nucleases, in the cytoplasm of cells
8
.  Studies have shown 
that a significant proportion of the mammalian genome is responsible for coding 
endogenous antisense transcripts
9,10
, however, synthetic siRNA molecules have also been 
constructed and transfected into cells
7
.  The resultant siRNA molecules contain a 
characteristic 5’-monophosphate group and 3’ dinucleotide overhang, critical for loading 
into the RNA induced silencing complex (RISC)
11
. In the processed siRNA duplex, one 
strand is preferentially selected as the “guide” strand for RISC loading, while the 
“passenger” strand is inevitably cleaved by the argonaute-2 protein (Ago2), thus 
facilitating its release and RISC activation
12,13
. Asymmetrical strand selection to guide 
RNAi depends on the thermodynamic stability of the 5’ end with the less  
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Figure 1.1. Three classical categories of antisense molecules and their respective 
precursors. A) long double stranded RNA (dsRNA) before being processed into small 
interfering RNA (siRNA). B) original micro RNA containing poly-A tail and loop 
structure before being cleaved.  The bubbles denote mismatches in base pairs and the 
miRNA* nomenclature indicates the passenger strand. C) PIWI-interacting RNA 
(piRNA) cycle regenerating antisense piRNA strands from reciprocal cleavage of sense 
and antisense transposon transcripts
6
.    
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thermodynamically stable 5’ strand being selected as the guide strand. In fact, it has been 
shown that a difference of a single hydrogen bond can direct strand selection
14
. In 
humans, RISC loading and recruitment of Ago2 recruitment (the catalytic enzyme in 
RISC responsible for target RNA scission) requires association of TRBP (the human 
immunodeficiency virus transactivating response RNA-binding protein) with siRNA 
bound to Dicer. This suggests that Dicer, Ago2 and TRPB are all involved in the RISC-
loading complex
15
. Ago2 and single-stranded siRNA together alone form a minimal 
RISC that could accurately cut target RNAs
16
, while determination of the crystal structure 
of Argonaute protein from Pyrococcus furiosus revealed distinct N-terminal, middle and 
PIWI domains with a Piwi Argonaute Zwille (PAZ) domain connected above the base via 
a “stalk” region. The PIWI domain resembles ribonuclease H, suggesting its function as 
“Slicer” responsible for target cleavage17. Further analysis of the crystal structure of 
Thermus thermophilus argonaute revealed the guide strands 5’-phosphate end is anchored 
in the Mid domain, while the 3’ end is anchored within the PAZ domain. This orientation 
permits Watson-Crick base-pairing with target mRNA between nucleotides 2-6 and 
cleavage at the 10-11 position
18
. Based on sequence similarity between the siRNA 
molecule and target mRNA, the mRNA transcript is either enzymatically cleaved (exact 
base pairing) or translationally repressed (inexact base pairing), however, the mechanism 
has not been completely illuminated
19,20
. The factor determining whether target RNA is 
degraded, or translationally repressed without degradation, is thought to depend on the 
degree of sequence matching between the siRNA and its target mRNA
21
. Perfect matches 
are thought to result in mRNA degradation while imperfect matches lead to translational 
repression. However, this rule is not always followed
22
. A schematic outlining the role of 
siRNA role in the RNAi pathway can be seen in Figure 1.2. Additionally, it is also 
important to note, especially when considering the issue of the amount of siRNA 
potentially needed to exert a therapeutic effect when siRNA-mediated reduction in 
disease-potentiating genes is proposed as a treatment strategy, that RISC is able to 
catalyze several rounds of RNA cleavage leading to gene silencing from only a few 
molecules of siRNA per cell
2,23
. 
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Figure 1.2. Schematic of siRNA being processed by Dicer and repressing mRNA 
translation through RISC. 
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1.3 siRNA therapy in disease treatment 
 Since every cell in the body possesses the intrinsic machinery required to process 
endogenous RNAi molecules and exogenous molecules designed to mimic endogenous 
RNAi
24
, and any RNA sequence can theoretically be targeted, there exists a plethora of 
diseases resulting from abnormal gene expression that could be suitable candidates for 
siRNA therapy. In general, antisense research has focused on areas where standard 
treatment options have been relatively ineffective or where improvement is desired and 
required. The list of diseases, infections, and pathological conditions in this category 
includes, but is not restricted to, viral infection
25,26
, age-related macular (AMD) 
degenerative diseases
27
, cancer
28,29
 (discussed further below), neurodegenerative 
diseases
30
, Duchenne Muscular dystrophy
31
, and Huntington Disease
32
. SiRNA strategies 
have also become powerful research tools to explore the consequences of gene silencing 
on disease progression. In one study, Karlas and colleagues utilized a genome-wide 
siRNA library composed of ~60,000 siRNAs targeting over 20,000 gene products to 
determine which host cell genes are critical for Influenza A virus replication
33
. Their 
conclusion was that siRNA therapy has enormous potential to generate increased 
understanding and to be applied to treatment of many diseases. The actual 
implementation of siRNA strategies is easier said than done, however, since factors such 
as tissue accessibility and siRNA delivery remain obstacles. Those factors are addressed 
below.  
1.4 siRNA in cancer therapy 
In Hanahan and Weinberg’s prominent paper on the Hallmarks of Cancer, one of 
the enabling characteristics contributing to cancer development is genome instability and 
mutation
34
. A central concept is that certain mutant genotypes will provide an advantage 
over other cells, and that those advantageous characteristics lead to their growth and 
dominance in the local environment. Whether it is the activation or upregulation of 
certain oncogenes or the downregulation of tumour suppressor genes (both are events 
leading to tumour progression), both are situations where siRNA strategies may be 
utilized to modulate abnormally-expressed genes. Conventionally, siRNA strategies are 
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employed to silence mRNA targets resulting in loss of gene function, however, 
alternatively they may also be utilized indirectly to upregulate certain genes of interest
35
. 
This can potentially be achieved by targeting miRNAs, which normally function to 
regulate over 100 different mRNA transcripts
36
. This may become even more critical 
when trying to target disease-causing gene products previously considered “non-
druggable” through application of standard strategies employing small molecules, 
proteins or antibodies to bind to and alter the activity of target molecules
37
. In some 
cases, treatment with siRNAs has led to the direct inhibition of cancer cells both in vitro
38
 
and in vivo
39
, while in other instances the use of siRNAs has re-sensitized cancer cells to 
chemotherapeutic drugs that have arisen during chemotherapy
38,40
, This is especially 
valuable when trying to reduce effective drug doses of chemotherapeutic drugs to limit 
side effects on patients. MacKeigan and colleagues used an RNAi screen to identify over 
650 human kinases and 220 phosphatases potentially implicated in apoptosis and 
chemoresistance, and were then able to subsequently downregulate a selected few and 
show enhanced apoptosis in cancer cells treated with low doses of the chemotherapeutic 
drug Taxol
41
, The ability to perform these robust RNAi screens using siRNA libraries is 
beginning to be even more critical as improvements in sequencing has revealed the 
highly heterogeneous nature of many cancer types and the abundance of genetic 
mutations they carry
42
. As a result, the development of more proficient tumour 
sequencing technology and the ability of siRNAs to, in theory, target any gene may allow 
for more effective personalized treatments where conventional therapeutic strategies are 
not sufficiently effective and/or are accompanied by toxicities such that cancers cannot be 
cured or controlled to a satisfactory degree. 
1.5 Targeting thymidylate synthase (TS) in cancers 
 With advancements in sequencing, bioinformatics and diagnostic tools such as 
those described above, genome-wide siRNA screens the discovery of cancer-associated 
genes is ever-growing
43,44
. Some of the gene targets undergo mutations prominent in 
specific cancer types (for example, a BRAF mutation occurring in 66% of malignant 
melanomas
45
), while others are more generally implicated in cancer progression (for 
example, those playing prominent roles in signaling pathways that control growth and 
10 
 
proliferation of a large fraction of tumour types). An example of a general target 
receiving attention is Ras, part of the mitogen-activated protein kinase (MAPK) pathway, 
which is mutated in approximately 15% of human cancers
44
. Another popular target is 
vascular endothelial growth factor (VEGF), due to its role in facilitating increased blood 
supply for tumour growth resulting from a transition from a dormant to active 
vascularization state. Reductions in tumour volume have been limited with the use of 
antiangiogenic agents alone. However, studies utilizing combinations of antiangiogenic 
molecules, such as those targeting thrombospondin-1 and VEGF, appear to be more 
promising
46
. 
 A putative siRNA target that has been well implicated in many cancers is 
thymidylate synthase (TS). TS protein enzymatically functions to catalyze the reductive 
methylation of deoxyuridylate (dUMP) to produce thymidylate (dTMP) with the N
5
,N
10
-
methylenetetrahydrofolate (CH2-THF) acting as the methyl group donor (Figure 1.3)
47
. 
Both normal and cancerous cells depend upon the TS-catalyzed reaction for DNA 
replication and repair as it provides the only de novo source of dTMP. With the enhanced 
reliance of cancer cells on TS for a source of dTMP in DNA replication during 
uncontrolled proliferation, TS has proven to be an attractive therapeutic anticancer target. 
Surprisingly, use of traditional TS protein small molecule inhibitors can actually lead to 
transiently elevated TS protein levels and subsequent drug resistance as depicted in 
several 5-fluorouracil (5-FU)-selected, drug resistant cell lines
48
. This is likely due, in 
part, to disruption of the autoregulatory feedback loop between TS mRNA and TS 
protein, whereby exposure to TS protein inhibitors leads to a decrease in intracellular 
unbound TS, resulting in enhanced TS mRNA translation and ensuing elevated TS 
protein levels
49
. Issues of TS protein drug resistance in many cases coupled with 
unwanted toxicity profiles have warranted an alternative approach to targeting TS 
function in cancer therapy. By targeting TS at the mRNA level problems of 
autoregulation and protein translation can theoretically be ablated, making an antisense 
approach attractive as a component of TS-targeted therapy. Initially, synthetic antisense 
oligodeoxynucleotides (ASOs), which facilitate mRNA degradation via ribonuclease H 
activation and exonuclease cleavage
50
, were implemented for TS mRNA silencing due to 
their enhanced stability through a 2’-O-(2-methoxyethyl) backbone modification51. These  
11 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Reductive methylation of deoxyuridylate (dUMP) to produce 
thymidylate (dTMP). N
5
,N
10
-methylenetetrahydrofolate (CH2-THF) acts as the methyl 
group donor.  
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ASOs enhanced cancer cells to TS inhibitors and reduced cell proliferation when used 
alone in vitro
52
. They were also able to reduce both TS mRNA and protein levels in 
tumour tissues when administered intraperitoneally
52
. As an alternative to synthetic ASOs 
and perhaps offering a more natural and potent route
53
, siRNAs have more recently been 
tested to reduce TS levels. In vitro, TS siRNA alone was able to reduce mRNA and 
protein levels over 80% and in combination with pemetrexed significantly reduced cell 
proliferation
28
. The effectiveness of using siRNAs targeting TS or any other gene, 
however, has largely been restricted to cell culture as problems arise when delivering 
siRNA in vivo. 
1.6 Challenges associated with antisense delivery 
   As mentioned above, ASOs are capable of accumulating in cultured cells in the 
absence of delivery agent (although only at relatively high concentrations that also induce 
toxicity; liposomal delivery vehicles are generally required to mediate uptake of lower, 
non-toxic concentrations)
54
 and in tumour tissue in vivo, which take up ASOs relatively 
efficiently without the use of exogenous delivery agents
55
. Alternatively, siRNAs are 
transfected into recipient cells in culture using a standard transfection agent such as 
Lipofectamine 2000. Administration of naked siRNA (no delivery agent or molecule 
modification) in vivo is inefficient for a number of reasons, especially when systemically 
administered, including: (1) limited cellular uptake across the plasma membrane due to 
repulsion of negative charges; (2) non-specific distribution and uptake into non-tumour 
tissues; (3) serum nuclease-mediated degradation; (4) reticuloendothelial system (RES) 
capture and renal elimination; and (5) inefficient capillary escape into tissues 
(extravasation)
56,57
.  
Consequently, to be implemented in vivo, siRNA molecules are usually 
administered in conjunction with some type of delivery agent. However, any 
systemically-delivered nanoparticle siRNA delivery agent must still overcome many 
hurdles: first it must evade filtration/renal excretion, phagocytosis by circulating and 
tissue-resident white blood cells, and degradation by plasma nucleases in the 
bloodstream. Thus it must be capable of movement across the vascular endothelial layer; 
14 
 
diffusion through the extracellular matrix (ECM); uptake by target cells; escape the 
endosome; and, finally, productive association with RNAi-processing complexes in the 
cytosol (Figure 1.4)
58,59
. Following systemic administration, siRNA delivery 
nanoparticles are preferentially taken up by the reticuloendothelial system (RES) 
composed primarily of macrophages and Kupffer cells present in RES organs such as the 
spleen and liver
60
. This process is further enhanced by serum proteins adsorbing to the 
surface of nanoparticles, thus promoting opsonization (complement activation) and rapid 
clearance
61
. Factors such as particle size, charge and surface properties can influence 
clearance and biodistribution (discussed in the section on PEGylating liposomes [Section 
1.7.3]). During siRNA biodistribution, siRNA particles leave blood vessels and enter the 
tissue interstitium. Diffusion across capillaries results from the difference in hydrostatic 
and osmotic pressures on either side of the blood vessel membrane. The type of 
endothelium in blood vessels also comes into play as major differences occur between the 
three types: continuous (e.g., arteries, capillaries); fenestrated (e.g., digestive mucosa); 
and discontinuous (e.g., liver)
61
. One advantage when trying to target tumours with 
siRNAs or other therapeutic molecules is their “leaky” vasculature compared to normal 
tissues. Tumour microvessels can have pores ranging from 100 to 780 nm in diameter, 
while normal capillaries can have pores <6 nm, which is why optimizing particle sizes 
can become important
58
. Leaky vasculature and lack of lymphatic drainage (characteristic 
of most solid tumours) has led to recognition of the Enhanced Permeability and Retention 
(EPR) effect, whereby systemically injected particles will tend to accumulate at the 
tumour site. One tradeoff, however, is that a lack of a lymphatic system actually increases 
interstitial fluid pressure from the centre of the tumour outward making passive diffusion 
of particles through the interstitium to the tumour border more difficult
62
. Once the 
nanoparticle reaches the tumour cell it must cross the cell's plasma membrane into 
cytoplasm. This is another major advantage to using a delivery agent, as naked siRNA is 
not favourably taken up across anionic cell membranes due to its high molecular weight, 
large size, and negatively charged phosphate backbone. Functionalizing siRNA carriers 
with ligands or antibodies can promote specific uptake and will be explored further when 
discussing targeting moieties (Section 1.8). Positively charged siRNA carriers generally 
associate with the negative plasma membrane and are internalized in cytoplasmic lipid 
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Figure 1.4. Barriers associated with various siRNA delivery methods. The three 
major areas depicted include circulation in the bloodstream, cellular uptake and 
intracellular trafficking
58
.  
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vesicles (endosomes) via endocytosis
63
. Upon internalization, the endosome will typically 
fuse with early endosomes before maturing into late endosomes and fusing with 
lysosomes for degradation. It is imperative that the siRNA/nanoparticles escape the 
endocytic vesicle prior to lysosome processing, otherwise they will be degraded before 
reaching the RNAi processing complex in the cytosol. A great deal of effort has gone into 
understanding the principles of endosomal escape and what properties promote it. 
Currently, it is hypothesized that there are two modes for siRNA carriers to facilitate 
endosomal escape: (1) polyplexes favour the proton sponge effect and umbrella 
hypothesis; while (2) lipid vesicles favour membrane destabilization via ion pair 
formation
64
. Briefly, cationic polyplexes are able to promote escape by acting as good 
buffering agents at pH 5-7. Normally, as early endosomes progress to late endosomes and 
eventually to lysosomes, the pH is lowered. However, by acting as buffers the polyplexes 
prevent acidification (they act as "proton sponges”) in the endosomes, resulting in proton 
influx and osmotic swelling
65
. This hypothesis has been further extended to include the 
umbrella hypothesis, whereby the polyplexes become protonated at a lower pH (5-6) 
causing a change in their conformation due to electrostatic repulsion of their recently 
protonated amine groups
64,66
. This extension coupled with the increase in osmotic 
pressure due to the “proton sponge” effect is presumed to facilitate endosomal rupture 
and escape. Alternatively, cationic lipid vectors are thought to promote endosomal escape 
via interactions with the anionic phospholipids forming the endosome. Close proximity of 
the cationic liposome lipids and anionic endosome lipids it thought to result in 
destabilization and formation of cationic-anionic ion pairs
67
. This new configuration 
presumes a cone shape and promotes the transition from a lamellar phase to an inverted 
hexagonal phase, which can be likened to the physical opening of a “zipper” with the 
siRNA content being released to the cytosol
68
. Regardless of the mode of endosomal 
escape, this barrier remains a major obstacle to efficiently delivering siRNA to RNAi 
processing complexes in cells. 
 Currently, siRNAs in clinical trials have been limited to local administration at 
sites near target tissues, such as the eye. Alternatively, they have taken advantage of the 
natural biodistribution of nanoparticles following systemic injection (for example, in 
testing siRNAs for treatment of liver cancer)(see Table 1.1 for examples of various  
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Table 1.1. Selection of siRNA therapies using various delivery techniques that 
currently or recently completed clinical trials. Legend: IV – intravenous injection; IVT 
– intravitreal injection; VEGF – vascular endothelial growth factor; PLK1 – polo-like 
kinase 1; KSP – kinesin spindle protein; PKN3 – protein kinase 3; RRM2 – 
ribonucleotide reductase; GM-CSF – granulocyte-macrophage colony stimulating factor; 
EphA2 – receptor tyrosine kinase; SNALP – stable nucleic acid lipid nanoparticle; AMD 
– age-related macular degeneration; NAION – non-arteritic anterior ischemic optic 
neuropathy; term – terminated; ongo - ongoing  
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siRNA delivery systems in clinical trials, and www.clinicaltrials.org for a complete list of 
siRNA therapies being tested in humans). These methods, however, are not viable for 
many specific cancers or other diseases, due to poor local accessibility and/or non-
advantageous patterns of tissue distribution after systemic administration. After 
discussing the many inherent barriers involved with the systemic delivery of siRNA 
delivery agents it is not surprising that an ideal delivery system should possess most or all 
of the following attributes: (1) safety: biocompatible, biodegradable and non-
immunogenic; (2) capacity to enhance tissue-specific distribution following intravenous 
injection; (3) deliver an effective amount of siRNA into target cells while protecting them 
from serum nuclease degradation and RES clearance; and (4) promote endosomal release, 
thus permitting the association of siRNA with RNAi machinery, and 5) be relatively 
simple and inexpensive to manufacture
57,58
. It is important to keep these general 
characteristics in mind when considering the advantages and limitations to the common 
siRNA delivery strategies described below. 
1.7 Overview of common siRNA delivery systems 
SiRNA delivery systems are broadly categorized as either viral or non-viral 
methods. For this project, only those methods considered non-viral will be explored. The 
non-viral methods can be further divided into 3 categories: physical, conjugation-
mediated, and carrier-mediated. The last of these three will be discussed in more depth as 
it relates to this project.  
 1.7.1 Physical delivery methods 
 One of the more straightforward and initial methods to deliver siRNA is via 
hydrodynamic injection. This method involves the intravascular injection of siRNA 
typically suspended in an aqueous buffer solution
69
. The advantage of this method is that 
siRNAs can be locally administered and concentrated in specific tissues, thus avoiding 
many obstacles (discussed above) associated with systemic delivery strategies. Typically, 
in murine models, a 10% injection volume to body mass ratio is administered
70
. 
However, and depending on the organ and injection site, this can be successfully lowered 
to <2%, as observed when attempting to achieve gene silencing in the liver through 
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hepatic portal vein injection
71
. Due to its invasive nature, hydrodynamic injection is not a 
realistic option for treatment of many disease types. However, there are a few situations 
(for example, age-related macular degeneration [AMD]) where some success has been 
achieved. Generally, intravitreal treatment with siRNAs is well tolerated by patients and 
has even helped to improve visual acuity
72,73
. Even though there are multiple sites 
surrounding the eye into which bioactive agents can be injected and from which those 
agents can be released into their site of action, it is still thought that the development of 
advanced nanocarriers can provide a more effective delivery system than ocular 
injections alone
72
. Such nanocarriers are now receiving more attention in planning 
strategies to apply siRNAs in a clinical setting.  
Another method, termed electroporation (EP), uses electrical pulses to facilitate 
the cellular uptake of material into cells
74
. The pulses are believed to create transient 
aqueous pores in the plasmid membrane, thus making them more susceptible to transit of 
macromolecules such as nucleic acids
75
. Its attractiveness stems from the ability to 
restrict delivery within a given area (electric field) with minimal side effects
76
. EP may 
not be suitable for all situations, including treatment of tumours deep within the body. 
However, EP-mediated transfection of VEGF-targeting siRNA was able to suppress 
tumour growth by 90% in mice
77
, and dermal EP of siRNA has been optimized to reduce 
GFP signal by 50% in guinea pig
75
.  
 A final method of physical delivery worth noting is the phenomenon of 
mechanical massage, whereby the application of light, physical pressure to an organ 
enhances exogenous nucleotide uptake from intravenous circulation. Initially shown to be 
effective in mice, with increased renal uptake following intravenous injection and later 
repeated in the spleen, this method is hypothesized to physically activate certain 
transcription factors that increase the accumulation of nucleic acids in the cells of the 
massaged tissue
78,79
. 
 1.7.2 Conjugation-mediated delivery 
 Another strategy taken to increase the delivery efficiency of siRNA is to 
conjugate them with a variety of moieties (e.g., small molecules, peptides, antibodies, or 
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aptamers) that improve stability and increase the time in circulation, increase the 
specificity of tissue accumulation, and increase cellular uptake and/or endosomal 
escape
80
. 
 For example, the small molecule cholesterol was conjugated to the 3’ end of 
siRNA (chol-siRNA) before being intravenously injected in mice. The modified chol-
siRNA) displayed enhanced serum stability, reduced plasma clearance and significant 
levels were detected in liver, heart, kidney, adipose and lung tissues 24 h following 
injection compared to the unmodified siRNA
37
. Recently, Parmer and colleagues 
conjugated poly(amido amine disulfide) polymer on the 5’ end of the passenger siRNA 
strand to enhance endosomal lysis and escape. They also took advantage of the acidic 
nature of endosomes to reduce cytotoxicity by additionally conjugating an acid labile 
poly(ethylene glycol)(PEG) molecule to mask the lytic activity of the polymer
81
. 
 Cell-penetrating peptides (CPPs) may also be complexed or conjugated with 
siRNA to increase their uptake across plasma membranes. They are typically amphipathic 
or cationic in nature, which aids them in transfer across the plasma membrane. Although 
still a controversial concept, it appears they are taken up via both endocytic and non-
endocytic mediated pathways
82
. Conjugation of the CPPs penetratin or transportin to 
siRNA showed competitive target knockdown and better sustained gene silencing over 3 
days compared to commercially available lipid-mediated transfection agents 
(Lipofectamine) in vitro
83
. 
 Association of antibodies with siRNA has been shown to enhance tissue specific 
targeting. Xia et al. first demonstrated in human epithelial cells an over 90% reduction in 
luciferase signal target following uptake of monoclonal antibody (mAb) against human 
insulin receptor conjugated to anti-luciferase siRNA
84
. They expanded on this work in 
vivo by achieving a 69-81% reduction in luciferase gene mRNA levels in rat glial cells 
implanted in adult rat brains using a transferrin receptor targeting mAb conjugated to 
siRNA
85
.         
 An emerging siRNA delivery strategy utilizes the conjugation of oligonucleotides, 
called aptamers, for increased delivery efficiency. Aptamers function in a fashion similar 
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to small molecules in that they are about the same size and therefore display similar 
clearance patterns. However, they also share characteristics with antibodies in that they 
tightly bind to targets in a specific manner and can modulate downstream pathways
86
. 
Aptamers can be designed against numerous targets and have the ability to differentiate 
between tumorigenic and normal cells
86
. Due to their ability to affect downstream 
regulators, aptamers alone are used to treat a number of diseases. However, their efficacy 
is believed to be improved when functionalized with other therapeutic molecules such as 
siRNA. The most well-studied of these aptamer-siRNA chimeric molecules are those 
designed to bind to cells expressing cell-surface receptor prostate specific membrane 
antigen (PSMA), a transmembrane protein highly expressed in human prostate cancer. 
“Second generation” PSMA-siRNA chimeras contain a truncated PSMA binding region 
that allows for large-scale synthesis while maintaining specificity; a 2-nt overhang on the 
siRNA 3’ end guide strand for greater accessibility to RISC; and an additional 
conjugation to PEG to increase serum stability for up to 5 days. These modifications 
resulted in significant regression of PSMA-positive tumours in athymic mice following 
intravenous injection
87
. Since aptamers are composed of nucleotides they face many of 
the same challenges as siRNAs. It is anticipated that further modifications to both 
aptamers and siRNAs will lead to potent anti-cancer chimeric molecules.  
 1.7.3 Carrier-mediated delivery           
 Carrier-mediated delivery vehicles are similar to conjugated ones in that they 
facilitate siRNA uptake into target tissues, with the difference that the siRNA and carriers 
do not form covalent complexes with the siRNA as the conjugate vehicles do. There are 
many types of nanoparticles that could be considered carriers for siRNA. For the 
purposes of this project, only carbon nanotubes (CNTs), polymer carriers, and lipid-
derived carriers will be discussed. 
 Carbon nanotubes (CNTs) are highly ordered, hollow carbon graphite 
nanomaterials shaped in a nano-needle structure giving them a large surface area for 
interactions
88
. Their shape would suggest they facilitate cellular uptake through physical 
penetration of the plasma membrane. However, recent studies indicate they enter via 
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endocytosis
88
. CNTs are capable of forming stable complexes with siRNA molecules 
through a mechanism driven by Van der Waals interaction whereby the siRNA duplex 
partially “unzips” and wraps around the CNT wall89. Alone, CNTs display poor 
dispersion and solubility in aqueous solutions: functionalized CNTs (f-CNTs) have been 
synthesized to solve these problems. An example of an f-CNT is the addition of PEG to 
the outer wall, which improves overall stability and hydrophilicity
90
. F-CNTS coated 
with PEG and an acid-labile disulfide group to enhance endosomal escape showed a 
higher silencing efficiency then the standard commercial transfection agent 
Lipofectamine. Much more work is needed with CNTs before they can become viable 
siRNA delivery vehicles in vivo
91
. 
 Cationic polymer delivery agents form strong electrostatic interactions with 
negatively charged siRNAs, thus forming polyplexes where the siRNA becomes 
condensed and protected from nuclease degradation
91
. Cationic polymers can be 
categorized as either natural or synthetic. Natural polymers have the inherent advantage 
of being biocompatible, biodegradable, and minimally toxic, while synthetic polymers, 
although designed to achieve high endosomal release and low enzymatic degradation, 
often exert undesirable toxicity
57
. Atelocollagen, an example of a natural polymer, when 
complexed with siRNAs targeting candidate genes of prostate cancer and administered 
systemically, induced selective and efficient inhibition of tumour growth in mice. The 
atelocollagen/siRNA complexes also showed great stability, remaining intact for over 3 
days while incurring no significant side effects or interferon response
92,93
. Poly-L-lysine, 
or polyethyleneimine (PEI), is the most studied synthetic polymer for delivering antisense 
molecules
58
. As a cationic polymer with a high charge density, PEI takes advantage of the 
“proton sponge effect” for efficient endosomal escape64. PEIs have been synthesized with 
various degrees of branching and molecular weights. Generally, a branched structure 
results in a higher transfection efficiency, while low molecular weight structures confer 
lower toxicity
94
. Urban-Klein and associates were able to reduce subcutaneous tumour 
growth in mice using a low molecular weight PEI complexed with siRNA targeting c-
erB2/neu (HER-2) receptor administered intravenously. The PEI/siRNA complexes were 
able to shield the siRNA from serum nucleases and did not induce any apparent toxicity 
to animals
95
. Similarly, systemic administration of a low molecular weight/siRNA 
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complex targeting VEGF did not induce liver damage or induce cytokines, but did 
efficiently deliver siRNA to subcutaneous tumours of pancreatic and prostate origin
96
. 
Recent strategies to further advance the efficiency and safety of cationic polymers 
include: combining them with liposomes (lipopolyplexes)
97
; functionalizing them with 
PEG
98
; and coating them with gold nanoparticles (AuNPs)
99
. 
 Liposomes are spheroid vesicles composed of a phospholipid bilayer and aqueous 
core. Due to their inherent amphipathic nature and well-studied pharmaceutical 
properties, liposomes have became attractive carriers for siRNA and other antisense 
molecules.
56
 While anionic, neutral and cationic liposomes have all been synthesized for 
siRNA delivery and have resulted in some successes (including initiation of a clinical 
trial using neutral liposomes)
100
, the general emphasis has been on cationic liposomes 
because of their efficient delivery of siRNA to cells. This is because stable complexes 
can naturally form from the electrostatic interaction of the positive lipids and negative 
siRNA molecules; the interaction of the positive lipids and negative plasma membrane 
during cellular uptake; and the mechanism by which the positive lipids facilitate 
endosomal escape once inside the cell
58
. The addition of negatively charged siRNA to 
cationic lipids spontaneously forms stable multilamellar structures that protect siRNA 
from serum nucleases and facilitates their uptake in cells
101
. There are numerous cationic 
lipids available that vary in the number of amines in their head group capable of being 
protonated (an event that affects siRNA binding and overall surface charge); the 
orientation between the head group and backbone; and the overall nature of the 
hydrophobic backbone itself (length and saturation)
102
. The addition of a helper neutral 
lipid such as dioleoylphosphatidylethanolamine (DOPE) or cholesterol helps by allowing 
the complex to adopt a nonbilayer structure: this is thought to be critical for transitioning 
to an inverted hexagonal phase and to ion pairing formation with the endosome, both of 
which facilitate siRNA release (previously described in Section 1.6)
27,103
. The size of the 
liposome particles is also an important factor. Considering the leaky vasculature of the 
tumour environment that results from the EPR effect, and the restrictions on siRNA 
carrier size imposed by serum clearance and RES entrapment, there is still a debate on the 
acceptable size limit of particles. While many believe 200 nm is appropriate as an upper 
limit, one study using synthetic 3D models to mimic the interstitial milieu suggested that 
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particles <100 nm were required to effectively and rapidly diffuse through membranes 
and tissues to reach target cells
104
. The size can largely be controlled through the 
synthesis process, which can range from the classic lipoplex protocol, to passive 
encapsulation or ethanol dilution (see Figure 1.5)
104
.  
 While cationic liposomes can enhance cellular uptake and endosomal release, 
their positive charge unfortunately enhances aggregation and opsonization in the 
bloodstream leading to RES uptake and decreased serum half lives
105
. This is what led to 
the advancements in the functionalization of liposomes such as the addition of PEG. 
These PEGylated liposomes have been shown to increase the overall transfection 
efficiency to prostate tumour xenografts in vivo by preventing systemic clearance and 
serum opsonization (see Figure 1.4)
105
. However, the incorporation of PEG was not 
without limitations. Repeated injections appeared to induce anti-PEG IgM, leading to 
accelerated blood clearance
106
. The generation of anti-PEG IgM did seem to become 
attenuated when siRNA was encapsulated in the core of PEGylated liposomes (i.e., 
passive encapsulation method) versus complexation of siRNA to the outside of the 
liposomes (i.e., lipoplex method)
107
. The presence of PEG on the surface of cationic 
liposomes has also been shown to inhibit cellular uptake and endosomal escape as it 
partially shields the positive charge. In fact, a 5 mol% solution of 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG-2000) 
completely abolished gene silencing and was not reinstated until the fraction was lowered 
to 1-2 mol%
60
. These issues have led to recent advancements in particle design such as 
the creation of stable nucleic acid-lipid particles (SNALPs), which contain a mixture of 
cationic and fusogenic lipids initially stabilized by a PEG coating. Following intravenous 
administration, the PEG coating is shed and the cationic interior remains, leading to 
increased transfection efficiency
108
. Tekmira Pharmaceuticals has further advanced 
SNALP technology by synthesizing the ionizable cationic lipid 1,2-dilinoleyloxy-3-
dimethylaminopropane (DLinDMA). A derivative termed DLin-KC2-DMA has now 
been developed, and shows heightened endosomal escape via a strong propensity for 
undergoing an inverse hexagonal transition at acidic pHs
109
. This technology has been 
implemented in a phase 1 clinical trial to treat primary and secondary liver. However, 
results are not yet published (see www.clinicaltrials.org for study details). Another  
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Figure 1.5. Illustration of common liposome synthesis techniques. The figure 
illustrates the fact that a higher percentage of siRNA molecules become encapsulated in 
the liposome when using the passive encapsulation method compared to the lipoplex 
method. Legend: SUV – small unilamellar vesicle 
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strategy to further enhance liposome/siRNA delivery, especially with regard to specificity 
(discussed above) is the inclusion of a targeting ligand capable of binding specifically to 
a tissue/tumour specific marker or receptor. This is discussed in the following section. 
1.8 Ligand targeting nanoparticles for enhanced uptake 
 Similar to the methodology underlying targeting conjugated delivery vehicles, 
liposomes can also be functionalized with different ligands to enhance cellular uptake in 
specific tissues. For example, while non-targeting PEGylated liposomes resist 
aggregation and have long half-lives they still end up in normal tissues as well as 
tumours: less than 5% of the initial dose is taken up by the tumour
110
. That is why, in the 
case of Tekmira Pharmaceutical’s SNALPs, those agents are currently only in 
development to target liver cancer because, physiologically, that is where the majority of 
nanoparticles will naturally accumulate
60
. Davis and colleagues, with the backing of 
Calando Pharmaceuticals, has a cyclodextrin polymer-based drug (CALAA-01) currently 
in phase 1 clinical trials: this is the first siRNA therapy systemically administered and 
targeted to transferrin-expressing solid tumours
111
. It is important to keep in mind that the 
targeting ligands to not direct the particles to specific tissues. However, they do enhance 
the uptake in the targeted tissues once they get there through receptor-mediated 
endocytosis. This was shown when both transferrin receptor targeted and non-targeted 
particles accumulated in the same amounts at the tumour site, but intracellular delivery is 
seen only in the targeted vesicles
112
. Many other ligands have been assessed to target 
cancer-related markers including: fibroblast growth factor receptors
113
; HER2
114
; and the 
folate receptor (FR)
115
. Folate receptors are the focus of the following section. 
1.9 Targeting liposomes via the folate receptor (FR) 
 Good cancer target candidates should have the following properties: homogenous 
expression on all target cells; binding with their ligand should facilitate internalization 
(endocytosis); a low degree of "shedding" of target molecules (i.e., release from cells); 
and they should play an important role in tumour cell viability such that downregulation 
(to avoid targeting) would lead to decreased survival and malignancy
116
. Many of these 
qualities are what make exploiting the FR on cancer cells an attractive strategy. Folic acid 
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(FA), an essential vitamin, is required for one-carbon reactions and the synthesis of 
nucleotide bases. Cells normally take up physiological levels of FA via the reduced folate 
carrier
117
 or, in some cases, the proton-coupled folate transporter
118
. Fortunately, neither 
of these transporters have an affinity for folate conjugates, so folate-functionalized 
particles are left to interact with FRs expressed on a select few cell types. Depending on 
the source of FR-expressing cells, 4 or 5 different FRs have been described. For the 
purposes of this study only FR-α (FOLR1) will be explored, although it is noteworthy 
that FR-β can be found on the surfaces of macrophages and hematopoietic 
malignancies119. FR-α is 38-44 kDa glycosyl phosphatidylinositol-(GPI-)anchored 
membrane protein normally found on the apical surfaces of many epithelial cells, 
where it would be inaccessible to intravenously administered folate therapies. It is 
constitutively overexpressed in many human cancers, especially those of ovary, 
cervix, endometrium, lung, kidney, breast, colon and brain origin120. In normal cells, 
proliferation is inversely correlated with FR expression and positively correlated 
with extracellular folate concentrations (EFC), since the EFC inversely regulates FR 
levels121. Therefore, it is believed that FR expression in many cancer types has 
arisen to allow for greater competition for the minimal folate concentrations (~2 x 
10-8 M) found in extracellular fluids122. It is difficult to directly assess the exact 
number of FR’s per cell, however, studies using radiolabeled folic acid derivatives 
indicate binding can range from 1-4 pmol/106 cells within the first 30 m depending 
on the cell type123,124. Upon binding with FA, the FR becomes internalized and brings 
FA or any FA-conjugated particles along with it, which is a good trait for a target. 
There does seem to be a debate on the fate of the folate conjugates, as monovalent 
folate particles (internalized via a single FR) are believed to cycle back to the plasma 
membrane after forming early endosomes, while multivalent folate conjugates 
(internalized via multiple FRs; i.e., liposomes, nanoparticles) are trafficked to late 
endosomes and lysosomes for degradation right away125. This needs to be 
considered when using FR-targeting liposome particles, but also offers an advantage 
as the late endosome pathway has a pH of around 5.0 that may be exploited by pH–
triggered molecules126. Another advantage of using the FR is that its ligand folate is a 
small, non-toxic molecule with low immunogenicity that binds to the FR with a high 
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affinity (Kd = 0.1 nM) even after being modified at it carboxyl end to permit lipid 
anchoring, making it a suitable conjugate for many particles127.               
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Objectives and Hypothesis 
The purpose of this project is to test the capacity of a folate receptor (FR)-
targeting liposome to deliver thymidylate synthase (TS) siRNA to the cytosol of FR-
positive cancer cells where it can activate the RNAi machinery. We first hypothesize that 
non-targeting liposomes will mediate siRNA uptake into cells more efficiently than 
naked siRNA alone. We further hypothesize that decoration of siRNA/liposome 
complexes with folate will enhance their capacity to deliver siRNA to FR-positive human 
tumour cells both in vitro and in vivo, as a strategy to increase antisense effectiveness. 
We test these hypotheses through three objectives. Firstly, we characterize the liposomes 
based on their siRNA encapsulation yield, particle stability and size, and ability to protect 
against serum nucleases. Next, we determine transfection efficiencies (cellular uptake) in 
vitro, and organ/tissue distribution of siRNA/liposome complexes following systemic 
administration in vivo. Finally, we assess the ability of the siRNA/liposomes to knock 
down their gene targets both in vitro and in vivo.     
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Chapter 2  
2 Materials and Methods 
2.1 Cell culture 
Cell lines shown to have various levels of folate receptor expression
120
 were chosen 
for experimentation. KB (human HeLa cell variant, cervical adenocarcinoma), A549 
(human adenocarcinoma), HeLa (human cervical carcinoma), OVCAR-3 (human ovarian 
adenocarcinoma), B16-F10 (mouse melanoma) cell lines were acquired from the 
American Type Culture Collection (ATTC). KB, HeLa and B16-F10 cells were gown in 
Dulbecco’s modified Eagle’s medium (DMEM)(GIBCO, Carlsbad, CA, USA) containing 
10% (v/v) heat-inactivated fetal bovine serum (FBS). A549 cells were maintained in 
Minimum Essential Medium Alpha Medium (AMEM) (GIBCO) supplemented with 10% 
(v/v) FBS. OVCAR-3 cells were cultured in Roswell Park Memorial Institute medium 
(RPMI) (GIBCO) supplemented with 20% (v/v) FBS. All cell lines were incubated at 
37
o
C in 5% CO2. Cells were typically passaged 1:10 by trypsonization 1-2 times a week 
and regularly frozen in 1:10 DMSO:FBS at -80
 o
C to maintain low passage numbers.  
2.2 siRNA sequence design 
 A 19 nucleotide sequence targeting human TS mRNA (TS siRNA)(coding region 
526-544) and a 19 nucleotide control sequence (C2 siRNA with no known target were 
synthesized by Dharmacon, Inc. (Lafayette, CO, USA)
28
. TS siRNA and C2 siRNA were 
labeled with Cyanine 3 (Cy3) on the 5’ end of their sense strands, yielding Cy3-TS 
siRNA and Cy3-C2 siRNA, respectively. The sequence constructs were: TS siRNA: 5’-
GGACUUGGGCCCAGUUUAU-3’ (sense) and 5’-AUAAACUGGGCCCAAGUCC-3’ 
(antisense); C2 siRNA: 5’-UGGUUUACAUGUUGUGUGA-3’ (sense) and 5’-
UCACACAACAUGUAAACCA-3’ (antisense).    
2.3 Materials and preparation of liposome particles 
 1,3-Dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), cholesterol, 1,2-distearoyl-sn-glycero-3-
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phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000), and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] 
(Folate-DSPE-PEG2000) were purchased from Avanti Lipids, Inc. (Alabaster, AL). All 
lipids were dissolved and stored at -20
o
C in a 9:1 chloroform/methanol solution.  
 2.3.1 Passive encapsulation protocol 
 The “passive encapsulation” protocol was characterized by the incubation of siRNA 
to the lipid film prior to the extrusion of the liposome particles and for the purposes of 
our project was the primary mode of particle synthesis. This differed from the less-used 
“lipoplex” protocol where siRNA was added to the fully formed liposomes following 
extrusion (discussed below). Using the “passive encapsulation” protocol, folate receptor-
targeting liposomes were constructed using one of two separate methods: the “folate 
before” method or the “folate after” method. In the “folate before” method DOTAP, 
DPPC, cholesterol and Folate-DSPE-PEG2000 (at lowest concentration) were mixed in a 
1:3.5:3.5:0.018 molar ratio and evaporated to complete dryness under vacuum, forming a 
lipid film. The lipid film was hydrated using a TS (fol-lip-TS siRNA) or control (fol-lip-
C2 siRNA) siRNA/protamine mixture at a molar ratio of 30:0.0037:1 
DOTAP:protamine:siRNA and incubated at 50-60
o
C for 10 min to form large 
multilamellar liposome-siRNA/protamine complexes in solution. The multilamellar 
liposome solution was then rigorously vortexed and sonicated for 2-5 m at 50-60
o
C in a 
bath sonicator. The sonicated solution was extruded sequentially through polycarbonate 
membranes of decreasing pore size (0.2 and 0.1 mm diameter pores). The resultant small, 
unilamellar liposome solution was kept at 50-60
o
C until it could be transfected into cells. 
The “folate after” method followed the same protocol as above with the exception that 
Folate-DSPE-PEG2000, in the same molar ratio, was added to the extruded unilamellar 
liposome solution following extrusion instead of to the lipid film. The liposomes and 
Folate-DSPE-PEG2000 were allowed to incubate for 1-2 h to allow folate integration. To 
construct the non-targeting (non-fol-lip-C2 siRNA or non-fol-lip-TS siRNA) liposomes, 
the above protocol was followed aside from the incorporation of Folate-DSPE-PEG2000 to 
the liposome solution. When an experiment called for PEGylated liposomes, DSPE-
PEG2000 was added to the extruded liposome solution in a molar ratio of 1:0.22 
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DOTAP:PEG for folate and 1:0.23 DOTAP:PEG for non-folated liposomes, respectively. 
 2.3.2 Lipoplex protocol 
 Folate decorated (fol-lip) and non-targeting (non-fol-lip) particles were synthesized 
in a similar fashion according to the “passive encapsulation” protocol (above), with the 
difference that the lipid film layer was hydrated with RNase-free water alone prior to 
extrusion. Following extrusion, the small unilamellar particles were lyophilized (freeze-
dried) and stored at -20
o
C. This allowed for stable storage of the liposomes until needed. 
Upon use, the liposomes were re-hydrated with RNAse free water. A selected amount of 
siRNA was then added to the re-hydrated liposomes and incubated for 20 m to allow for 
the negatively charged siRNA to electrostatically complex with the positive liposomes.    
2.4 In vitro assessment of lipsome-Cy3 siRNA uptake using flow cytometry 
 Cells (KB, A549, HeLa, OVCAR-3 or B16 F10) were seeded in either 6 or 12 well 
Falcon tissue grade plates at concentrations ranging from 1-2 x 10
5
 cells/well depending 
on the experiment. Two h prior to transfection the media was replaced with either folate-
free RPMI or 1 mM folate RPMI depending on the experiment. Twenty four h after 
seeding the cells were with incubated with either non-fol-lip-Cy3-C2 siRNA or fol-lip-
Cy3-C2 siRNA to assess the difference in uptake based on FR targeting. Initially, both 
non-fol-lip-C2 siRNA and fol-lip-C2 siRNA were used as controls. However, they did 
not yield significant differences in background Cy3-positivity from a non-treated control 
(NTC). In general, media was aspirated and cells washed with phosphate-buffered saline 
(PBS) 4 h after addition of liposomal preparations (and at different times under 
circumstances where incubation times were varied) before being replaced with fresh 
media. The cells were then trypsinized and resuspended in 250-300 μl of PBS prior to 
analysis by flow cytometry. 
2.5 Confirmation of lipsome-Cy3 siRNA uptake in vitro by fluorescent microscopy 
 Cells were seeded in plates according to the same protocol described above (section 
2.4). Twenty four h after seeding the cells were incubated with either non-fol-lip-Cy3-C2 
siRNA or fol-lip-Cy3-C2 siRNA. Twenty four h following addition of liposomal 
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preparations, media was removed and cells were rinsed (2x) with PBS and replaced with 
fresh media to remove any excess liposome particles in the media. The cells were then 
imaged using by fluorescent microscopy.  
2.6 Assessment of TS silencing in vitro using lip-Cy3-TS siRNA 
 2.6.1 RNA extraction 
 Cells (KB and A549) were seeded in plates according to the same protocol 
described above (section 2.4). Twenty four h after seeding the cells were incubated with 
TS targeting non-fol-lip-Cy3-TS siRNA or fol-lip-Cy3-TS siRNA. Non-fol-lip-Cy3-C2 
siRNA and fol-lip-Cy3-C2 siRNA were used as negative controls. Twenty four or 48 h 
following transfection, the cells were washed twice with PBS and harvested using TRIzol 
(Invitrogen, Carlsbad, CA, USA) for RNA isolation. Chloroform (Bioshop, Burlington, 
ON, CA) was added to the cell-TRIzol solution and phase separation through 
centrifugation allowed for RNA purification and extraction in the top aqueous layer. 
RNA was then precipitated out of solution using isopropanyl (Bioshop). The RNA-
isopropanyl solution was centrifuged to form a RNA pellet before the isopropanyl was 
decanted. The RNA pellet was then suspended (2x) in 75% ethanol to remove any 
impurities (excess salts and proteins). The 75% ethanol solution was removed and the 
RNA pellets were dried for 30 m. Any remaining liquid was removed using an 
autoclaved Q-tip. The remaining RNA pellet was re-suspended in 20 ul of RNAse free 
water. RNA was quantified using Nanodrop’s ND-1000 Spectrophotometer (Wilmington, 
DE, USA)). RNA quality (degradation) was assessed on a 1% agarose gel run at 50V for 
20-40 m and imaged using Bio-rad’s Gel Doc (Mississauga, ON, CA).  
 2.6.2 Reverse Transcription  
 RNA (1 ug per reaction vessel) was then reverse-transcribed (RT) using Moloney 
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) in the presence of dNTPs, 
random primers and DDT. The RT reaction was carried out under the following 
conditions: 
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Table 2.1. Reverse Transcription reaction cycle parameters 
Temperature (
o
C) Duration (h) Function 
25 00:10:00 Primer attachment 
37 1:00:00 Polymerization 
4 00:05:00 (+ HOLD) Prevent degradation 
The synthesized complimentary DNA (cDNA) was stored at -20
o
C until it was needed for 
quantitative PCR (qPCR).  
 2.6.3 Quantitative PCR 
 cDNA (1 μl) was used per reaction vessel (50 ng cDNA assuming 100% RT 
reaction). qPCR reactions used TaqMan Gene Expression Master Mix (Applied 
Biosystems, Foster City, CA) in an Applied Biosystem’s ViiA7 qPCR machine. The TS 
specific forward and reverse primers were purchased from Applied Biosystems and used 
at a final concentration of 600 nM. The primer sequences for human TS were: 5’-
GGCCTCGGTGTGCCTTT-3’ (forward) and 5’-GATGTGCGCAATCATGTACGT-3’ 
(reverse). A TaqMan MGB probe labeled with 6-FAM (Applied Biosystems) was used at 
a concentration of 200 nM. It had a sequence of 5’-6-FAM-
AACATCGCCAGCTACGCCCTGCMGBNFQ-3’. A pre-designed human GAPDH 
labeled with FAM and MGB probe (Applied Biosystems) was used as an endogenous 
control. All individual samples/controls were run in triplicate in a 384 well plate. 
Standard curves (when applicable) were constructed from one of the unknown samples 
using a dilution series ranging from 1000 to 15.6. The parameters of the qPCR run are 
shown below: 
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Table 2.2. Quantitative PCR cycle parameters 
Temperature (
o
C) Duration (m) Function 
50 02:00 Optional 
95 10:00 Initial denaturation/ 
polymerase activation 
95 00:15 (40 cycles) Denaturation 
60 01:00 (40 cycles) Primer alignment and 
polymerization 
qPCR results were analyzed in the Life systems software using one of two methods: 
ΔΔCT method or the standard curve method. The ΔΔCT method was primarily used when 
comparing several treatment groups to the same control, thus yielding relative quantities, 
while the standard curve method helped to verify amplification and overall qPCR 
reaction efficiencies and assess statistical significance between groups (further explored 
in the Discussion section)
128
. 
2.7 Liposome particle size and zeta potential 
 Folate decorated (fol-lip-Cy3-C2 siRNA) and non-targeting (non-fol-lip-Cy3-C2 
siRNA) liposomes were prepared according to our protocol. The particles were diluted in 
RNAse-free water and mean particle diameter and surface charge (zeta potential) was 
assessed using a Zetasizer Nano Series instrument (Malvern Instruments Ltd., UK) 
according to the manufacturer’s protocol.  The instrument counts approximately 200,000 
particles/second until a stable reading is obtained. Particle size was measured over 
several time points to investigate particle aggregation and overall stability over time.  
2.8 Liposome:siRNA binding capacity assay 
 Lyophilized aliquots of PEGylated liposomes synthesized according to the 
“lipoplex” protocol were re-hydrated in 200 μl of RNAse-free water. Varying siRNA 
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quantities were added to the re-hydrated liposomes yielding liposome:siRNA molar 
weight ratios of 35, 30, 25, 20, 15, 10. Following a 20 m incubation, the PEGylated 
“lipoplex” lip-Cy3-C2 siRNA mixtures were run on a 1% agarose gel at 50 V for 30-40 
m and imaged using a Biorad imaging system.    
2.9 Nuclease degradation assay 
 Folate decorated (fol-lip-Cy3-C2 siRNA) and non-targeting (non-fol-lip-Cy3-C2 
siRNA) PEGylated liposomes were synthesized according to the “passive encapsulation” 
protocol. Liposomes were aliquoted into 1.5 mL centrifuge tubes yielding approximately 
0.71 nM of siRNA (before extrusion) per timepoint (0, 1, 2, 4, 8, 24, 48 h). The liposome 
aliquots were then incubated in a 1:1 (v/v) ratio with FBS (contains serum nucleases). 
Samples were incubated at 37
o
C (0 h) and transferred to -80
o
C at their specific timepoint 
to halt plasma nuclease activity. Free Cy3-C2 siRNA in mouse plasma was used as a 
positive control. Following the final timepoint, samples were thawed at room temperature 
and siRNA was extracted according to the TRIzol RNA extraction protocol described 
previously. Following suspension in RNAse free water, siRNA quantities were measured 
using the ND-1000 Spectrophotometer (Nanodrop). Equal amounts of siRNA were mixed 
with 6 x loading buffer (Table 2.3) and run on a 15% acrylamide TBE-PAGE gel at 80V 
for 1.5 h. The gels were incubated in ethidium bromide (50 μg/mL) for 8-10 m and 
imaged using Bio-rad’s image doc.   
Table 2.3. Recipe for 6x loading buffer used in assessing siRNA degradation 
Amount Reagent 
3 mL 100% Glycerol 
3 mL 0.5 M EDTA 
3 mg Bromophenol blue 
3 mg Xylene cyanol 
4 mL Sterile water 
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2.10 Ribogreen siRNA quantification assay 
 siRNA concentration in liposomes was quantified using the Quant-iT RiboGreen 
RNA kit (Invitrogen) according to their protocol. A high-range standard curve (assay 
points: 0 ng/ml, 20 ng/ml, 100 ng/ml, 500 ng/ml and 1 μg/ml) was constructed from a 
dilution series of 2 μg/ml siRNA stock solution. Liposomes were constructed according 
to the “passive encapsulation” and “lipoplex” protocols above, with the difference that 
siRNA was not incubated with protamine prior to addition to the lipid film layer as it 
prevented RiboGreen dye binding to siRNA. Liposome samples were diluted with TE 
buffer (10mM Tris-HCl, 1 mM EDTA, pH 7.5) over a range of 0.1 to 0.01 of the original 
sample concentration to fall within the standard curve. The diluted samples were 
incubated in a 1:1 (v/v) ratio with Quant-iT RiboGreen working solution for 10 m and 
read in a fluorescent microplate reader (490 nm excitation, 525 nm emission).  
2.11 Folic Acid inclusion assay 
 According to the “passive encapsulation” protocol, folate-decorated liposomes were 
synthesized by both the “folate before” and “folate after” methods. No siRNA/protamine 
mixture was added during synthesis as it interfered with the absorbance readings of folate 
ligand. A standard curve was created using a dilution series of free Folate-DSPE-PEG2000 
in RNAse free water. Absorbance readings were taken at 285 nm using a UV-Vis 
spectrophotometer (Beckman Coulter, Mississauga, Ontario) 
2.12 Mouse Models 
 NIH-III nude mice (6-8 week old females) were purchased from Charles River 
Laboratories International, Inc. (Wilmington, MA). Mice were maintained under a 
pathogen-free environment in the Victoria Hospital barrier facility. All experiments were 
conducted in accordance with the standard operating procedures set forth by the Canadian 
Council on Animal Care and Western University Animal Use Subcommittee. 
   2.13 FR expression of cultured cells using flow cytometry 
 KB, A549, HeLa, and OVCAR-3 cells were plated at a concentration of 2 x 10
5
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cells/T25 flask. Twenty four h after plating, media was aspirated and 1 ml of 10 mM 
EDTA was added to each flask. They were then incubated at 37
o
C for 10-15 m or until 
most of the cells could be seen detached under the microscope. Four ml of fresh media 
was added to each flask and the contents were dispensed into appropriate flow cytometry 
vials. Samples were centrifuged at 12,000 rpm for 8 m and washed with fresh PBS. 
Following re-centrifugation the PBS was decanted and primary monoclonal mouse IgG1 
FOLR1 or isotype antibody (R & D Systems, Inc., Minneapolis, MN) was added to each 
sample (2.5 ug/10
6
 cells). Cells were incubated in primary antibody (1
o
 ab) for 30-40 m at 
4
o
C. Samples were then centrifuged and washed again in PBS to remove any unbound 
antibody. Eight μl of phycoerythrin-conjugated anti-mouse IgG secondary antibody (IgG-
PE 2
o
 ab)(R & D Systems) was added to each sample and incubated in the dark for 30 m 
at 4
oC. Cells were then washed again with PBS and resuspended in 300 μl of PBS for 
analysis by flow cytometry.  
2.14 FR expression in vivo and in vitro, assessed by immunoblot 
 2.14.1 Tissue harvesting/protein extraction 
 NIH-III mice were subcutaneously inoculated with 2 x 10
6
 KB cells. Tumours were 
measured twice per week with hand calipers (Mitutoyo, Kawasaki, Japan) and mice were 
sacrificed when tumour volumes reached approximately 600 mm
3
. Tumour tissue was 
extracted, placed on dry ice and stored at -80
o
C until needed. A small (<0.5 g) sample of 
tumour was excised and suspended in 150 ul of cell lysis buffer (see Table 2.4 for recipe). 
The solid tumour tissue was disrupted using a hand homogenizer until it was evenly 
distributed throughout the lysis buffer. To process cells grown in vitro for immunoblot, 
cells were plated at 2 x 10
5
 cells/T25 flask and removed from the flask mechanically 
using a cell scraper 24 h after seeding. One hundred and fifty μl of cell lysis buffer was 
added to each cell pellet. Both in vivo and in vitro samples were processed following the 
same protocol from this point forward. Samples were placed on ice for 20 m with 
vortexing every 5 m before being centrifuged at 12,000 g for 10 m (4
o
C). The protein 
containing supernatant was collected and kept on ice. 
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Table 2.4. Sample lysis buffer for immunoblot 
Amount Reagent 
0.88 g NaCl 
2 mL 1M Tris-HCl (pH 7.6) 
1 mL 10% SDS 
1 mL Triton X-100 
500 ul 0.2M EDTA 
100 mL Deionized water 
 2.14.2 Protein quantification 
 Total protein content was quantified using a Bradford Assay. A standard curve was 
constructed using a dilution series from a 10 mg/mL working solution of bovine serum 
albumin (BSA). Samples were diluted in PBS (1:350) and diluted (6:4 reagent:PBS) 
Bradford reagent was added to each sample. Each sample was then distributed in 3 wells 
of a 96 well plate and read on a fluorescent microplate reader. Protein quantities were 
determined from the standard curve. 
 2.14.3 Gel electrophoresis and protein transfer 
 Separate gels were required to detect FOLR1 and endogenous control protein actin 
due to their similar size and the FOLR1 antibody requiring non-reducing conditions. 
Samples were mixed 1:1 (v/v) in 2x sample loading buffer (see Table 2.5 for recipe) and 
actin samples (reducing conditions) were heated at 90
o
C fro 5 m prior to gel loading. A 
20% acrylamide gel was used as it yielded the cleanest protein bands. Ten μg and 25 μg 
of protein suspended in a total volume of 35 ul were loaded into each well for FOLR1 
and actin detection, respectively. Following sample loading the gels were run at 120 V 
for 1 h 40 m in a standard Bio-rad gel electrophoresis apparatus. After the allotted time, 
the gels were removed and the area containing the assessed proteins were excised from 
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the gel and placed in transfer buffer along with the nitrocellulose film. A “transfer 
sandwich” was constructed and the transfer apparatus was run on 100 V for 1 h at 4oC.  
Table 2.5. Recipe for 2x sample loading buffer  
Amount Reagent 
3.05 mL Deionized water 
1.25 mL 0.5 M Tris-HCl (pH 6.8) 
3 mL 100% Glycerol 
2 mL 10% SDS 
0.2 mL 0.5% Bromophenol blue 
Store in 950 ul aliquots at -20
o
C  
50 ul (added to 950 ul aliquot before use) 2-Mercaptoethanol 
 2.14.4 Blocking, antibody labeling and imaging 
 The nitrocellulose membrane was removed from the “transfer sandwich” and 
blocked with 5% skim milk for 1 h. The paper was then washed several times in TBS-T 
(15 m, 5 m, 5 m) before being incubated with either primary monoclonal mouse IgG1 
anti-FOLR1 antibody(1:1000)(R & D Systems) or polyclonal rabbit IgG1 anti-β actin 
antibody(1:2000)(Santa Cruz Biotechnology, Dallas, Texas) in 1% skim milk for 1 h. The 
nitrocellulose film was washed in TBS-T several more times (15 m, 10 m, 10 m) to 
remove unbound primary antibody. The nitrocellulose film was then incubated with 
secondary antibody (when detecting FOLR1, 1:2000 anti-mouse-horse radish peroxidase 
[HRP],GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK) and, when 
detecting β actin, 1:10,000 anti-rabbit-HRP (GE Healthcare UK Limited) in 1% skim 
milk for 45 m. The nitrocellulose film was then washed again several times in TBS-T (15 
m, 5 m, 5 m) before being blotted with filter paper. Approximately 1 ml of HRP substrate 
(GE Healthcare UK Limited) was added to each nitrocellulose film fragment for 1-2 m, 
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and then blotted away using filter paper. The proteins to be detected were then imaged 
using a 860 Storm scanner (Molecular Dynamics, Baie d’Urfe, Quebec).      
2.15 In vivo distribution of Cy3 siRNA using folate receptor-targeting liposomes  
 Non-targeting (non-fol-lip-Cy3-C2 siRNA) and folate decorated (fol-lip-Cy3-C2 
siRNA) liposomes were synthesized according to the “passive encapsulation” protocol. 
Non-targeting or FR-targeting liposomes were injected into tail veins of NIH-III mice 
bearing two KB xenografts (one in each flank) of approximately 600 mm
3
 each. The 
amount of Cy3 C2 siRNA used was 50 μg/mouse prior to extrusion. There were 3 mice 
per treatment group. Mice were sacrificed 6 h following injection and various tissues 
(tumour, heart, skin, kidney, liver, muscle, connective tissue and intestine) were collected 
and placed in cryostat holders (Tissue-Tek, Torrance, CA, USA) and suspended in OCT 
(Tissue-Tek) and stored at -80
o
C. The cryostat samples were then sectioned in 10 um 
sections using a cryostat (Leica Biosystems, Concord, Ontario) and mounted on glass 
slides for fluorescent microscopy.  
2.16 In vivo silencing of TS using folate receptor-targeting liposomes  
 Non-targeting (non-fol-lip-Cy3-TS siRNA) and folate decorated (fol-lip-Cy3-TS 
siRNA) liposomes were synthesized according to the “passive encapsulation” protocol. 
Folate decorated liposomes containing C2 siRNA (fol-lip-Cy3-C2 siRNA) were used as a 
negative control. NIH-III mice were inoculated subcutaneously in two areas on their 
backs with 2 x 10
5
 KB cells/inoculation. Liposomes were injected into tail veins of NIH-
III mice (50 μg/injection before extrusion) 2 days following KB tumour inoculation and 
thereafter once per week for a total of 4 injections. There were 6 mice per treatment 
group. Mouse body mass was monitored twice a week and tumour size was evaluated 
twice a week using calipers. Twenty four h following the final treatment, the mice were 
euthanized and tumour tissue was harvested and stored at -80
o
C.  
 Several days later, the tumour tissue was thawed and a small amount (<0.2 g) was 
analyzed by qPCR for specific RNA levels. Tumour tissue was placed in TRIzol 
(Invitrogen) for RNA isolation and completely disrupted using a hand homogenizer. 
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From this point the protocol used for analyzing in vitro target mRNA reduction was 
followed (above, section 2.6.1). 
2.17 Statistical analysis 
 Data is presented typically as means ± standard deviations. Differences between 
experimental groups were analyzed using a Student’s t test Test and differences with p 
values less than 0.05 (confidence limit selected a priori) were considered to be 
significant.  
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Chapter 3  
3 Results 
3.1 Characterization of the liposome particles 
3.1.1 Liposome surface charge (zeta potential) and size as determinants of 
particle stability  
 A common indicator to determine a nanoparticle's overall stability in solution is to 
measure its zeta potential. Nanoparticles with an overall net charge will attract oppositely 
charged ions to its surface, forming a Stern layer. As the particle moves in solution an 
electrostatic potential is created between the two layers, which is called the zeta potential 
and is directly related to the surface charge of the particle
129
. The zeta potential of both 
non-targeting and folate-decorated liposomes with folate added either before (“folate-
before”) or after (“folate-after”) the extrusion process was measured either alone or in the 
presence of siRNA (Table 3.1). An example of a typical readout of zeta potential can also 
be seen in Figure 3.1. As expected, the zeta potentials are all positive since the liposomes 
contain cationic lipids. The zeta potential increased in the non-targeting liposomes when 
no siRNA was present, since siRNA carries a net negative charge from its phosphodiester 
backbone. Surprisingly, the same was not observed with the “folate before”-decorated 
liposome. This may have resulted from a lack of siRNA entrapment by the liposome 
particle or differences in the amount of folate-DSPE that integrated into the liposomes 
(discussed below). The folate-DSPE molecule carries a net charge between -1 and -2 
depending on the aqueous environment. In an attempt to balance the surface charges of 
the non-targeting and folate decorated liposomes, PEG, which contains an overall net 
charge of -1, was added to the non-targeting liposomes. It is difficult to be exact, 
however, due to the protonating nature of the folate-DSPE molecule. Unexpectedly, the 
"folate after" liposomes had a slightly higher zeta potential, which is likely influenced by 
the small sample size and amount of siRNA that had been included following the 
extrusion process. Regardless, a zeta potential around +30 or greater is considered 
strongly cationic and lead to relative stability
129
.  
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Table 3.1. Zeta potentials of various liposome particle mixtures. Non-targeting (non-
fol) and FR-targeting (fol) liposomes with folate inserted either prior to (fol before) or 
following the extrusion process (fol after) were synthesized in the presence (+siRNA) or 
absence (-siRNA) of siRNA. Samples were diluted 1:10 in water and analyzed for size 
and charge using the Malvern Zetasizer. Legend: N – is number of individual 
experiments; n – number of individual samples. 
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Sample Zeta Potential (mV) Sample size 
Non-fol-Cy3-C2RNA 
(+siRNA) 
29.42 ± 2.53 N = 3; n = 9 
Non-fol-Cy3-C2RNA        
(-siRNA) 
42.8 ± 3.88 N = 2; n = 6 
Fol-Cy3-C2RNA (fol 
before)(+siRNA) 
26.7 ± 5.72 N = 2; n = 6 
Fol-Cy3-C2RNA (fol 
before)(-siRNA) 
27.07 ± 1.34 N = 1; n = 3 
Fol-Cy3-C2RNA (fol 
after)(+siRNA) 
36.7 ± 1.55 N = 1; n = 3 
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Figure 3.1. Example of zeta potential readouts for liposome samples. Liposomes were 
synthesized according to the “passive encapsulation” protocol and kept at ~55oC until the 
measurements were performed soon after synthesis. Samples were diluted 1:10 in water 
and analyzed for size and charge using the Malvern Zetasizer. A) Zeta potential profile 
for non-fol-Cy3-C2RNA; B) zeta potential profile for fol-Cy3-C2RNA.  
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Another important attribute of a nanoparticles is size (diameter). As described 
above, smaller sizes (< 200 nm) are preferred for effective exit from the blood stream and 
entry into extracellular space, and enhanced uptake especially through the interstitial 
tissue in vivo
104
. A measure of particle size change over time is also an indicator of a 
particle’s overall stability. Zeta potential is the primary indicator of stability. However, 
changes in particle size can show how long the particles last in solution before becoming 
unstable and aggregating to form larger particles with less capacity to be taken up by 
cells. Examples of stable and aggregating particles as well as particle stability over time 
can be seen in Figure 2. Looking at the particle size readouts, a single normal distribution 
can be seen up until the 6 h time point indicating good particle stability (Figure 3.2A). At 
the 12 h time point, some aggregation has taken place as a distinct peak can also be seen 
at a size >1000 nm (Figure 3.2B). A particle stability >6 h is important because in some 
cases it could be several hours from the time of synthesis before the particles are 
transfected into cells or injected in mice, where a relatively homogenous liposome 
mixture is ideal. The sizes of the non-targeting and folate-decorated liposomes are 
similar, which is an important aspect to consider when comparing the two groups in vitro 
(sedimentation effect) and in vivo (RES entrapment and EPR effect). 
3.1.2 Folic acid decoration on liposome 
 A primary goal was to assess differences in cellular uptake between non-targeting 
and folate-decorated liposomes in FR-positive and FR-negative cell lines. Therefore, the 
actual amount of folate-DSPE that was incorporated into liposomes was considered. 
Folate was either added to the liposomes according to the “folate before” or “folate after” 
protocols. Absorbance readings at 285 nm indicated that 3.92-9.16% and 9.56 ± 0.34% 
(N=2) of folate-DSPE successfully integrated into the liposomes using the “folate before” 
and “folate after” synthesis protocols. This was not as high as reported in the literature 
(see Discussion section) and may have had an impact on experiments described below.  
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Figure 3.2. Liposome particle size and stability over time. Liposomes were 
synthesized according to the “passive encapsulation method” and assessed for size and 
charge using the Malvern Zetasizer. Liposome solutions were kept at ~ 55
o
C until the 
specific time point. A) Size distribution profile of fol-Cy3-C2RNA (+PEG) liposomes 
immediately after synthesis; B) size distribution profile of fol-Cy3-C2RNA (+PEG) 
liposomes 12 h following synthesis; C) liposome particle stability over a 12 h period with 
vertical bars displaying the size range.  
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3.1.3 siRNA binding/encapsulation yield 
 Another important property of liposome particles is their capacity to interact with 
siRNA. This would include siRNA electrostatically interacting with the cationic lipids or 
being encapsulated during the extrusion process. Liposome particles were synthesized 
using one of two methods: the “passive encapsulation” protocol (see Materials and 
Methods, Section 2.3.1) and the “lipoplex” protocol (see Materials and Methods, Section 
2.3.2).  
In the “lipoplex” protocol, liposomes were first synthesized alone and then siRNA 
was added after. In this case it was valuable to know how much siRNA a given amount of 
lipid was capable of binding. To assess this, liposome:siRNA complexes with different 
mass ratios (i.e., different amounts of siRNA associated with liposomes) were incubated 
and separated by agarose by gel electrophoresis (Figure 3.3). SiRNA disassociated from 
liposomes has high electrophoretic mobility, and visualization of that highly mobile 
siRNA was a measure of the capacity of liposomes to encapsulate the nucleic acids. 
Wells containing various amounts of free siRNA were included for reference. This is an 
indirect measure of binding ability since the bright white bands depict unbound siRNA. 
Liposome-bound siRNA remains in the wells (at the top of the photograph). It appears 
that a residual amount of free siRNA remained unbound regardless of the amount added. 
This could be due to the presence of negatively charged PEG molecules present on the 
surface of the liposomes. The amount of unbound siRNA increased at liposome:siRNA 
molecular mass ratios of 15 to 10 and this set the upper limit of the liposome-siRNA 
binding capacity at 12:7.2 DOTAP:siRNA molar mass using the “lipoplex” method. 
Therefore, during the course of experimentation, values below this threshold were used.  
The above method was used to qualitatively determine the amount of siRNA the 
liposomes could bind. However, a quantitative method would be more useful, especially 
one that could differentiate siRNA on the inside or outside of the liposomes. Therefore, 
RiboGreen dye was used to detect siRNA. RiboGreen fluoresces when bound to free 
siRNA, with the advantage that it differentiates between siRNA bound to the interior or 
exterior of the liposome since the lipid bilayer is impermeable to the dye, which can  
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Figure 3.3. Qualitative measurement of the siRNA binding capacity of liposomes 
synthesized using the “lipoplex” method. Liposome solutions were aliquoted into 
uniform amounts and then incubated for 20 m with various amounts of siRNA creating 
the following liposome:siRNA molar mass ratios of 35, 30, 25, 20, 15 and 10. The 
samples were then run on a 1% agarose gel. The white bands indicate unbound siRNA. 
Wells containing siRNA only (0.34, 0.48 and 1.20 μg) were included for reference. 
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interact with interior siRNA only when the liposome:siRNA complex is treated with a 
surfactant (i.e., Triton X-100) to release interior nucleic acid. Liposomes were 
synthesized according to the “passive encapsulation” and “lipoplex” protocols and 
incubated with RiboGreen working solution in the presence or absence of Triton X-100. 
RiboGreen fluorescence measurements were used to determine the percentage of total 
siRNA entrapped by the liposomes (bound on either interior or exterior) and percentage 
of total siRNA encapsulated by the liposomes (interior only)(Table 3.2). Several 
amendments to our protocol were necessary, as we found that RiboGreen dye could not 
bind siRNA complexed with protamine (data not shown). This made quantification of 
siRNA encapsulation possible only in material produced by a protocol that approximated, 
but did not exactly reproduce the “passive encapsulation” synthesis protocol. 
Furthermore, it appears that RiboGreen cannot bind siRNA well when it electrostatically 
interacts with an intact liposome (Table 3.2). This became evident as the percentage of 
siRNA encapsulated following extrusion was 80 and 86% for the “lipoplex” and “passive 
encapsulation” protocol, respectively, when theoretically the maximum amount of siRNA 
that should occur on the interior from the passive encapsulation protocol is 50% and, in 
the lipoplex method, much less because the siRNA is added to the exterior of preformed 
liposomes. Therefore, it is hypothesized that the RiboGreen assay can accurately quantify 
only the total amount of siRNA entrapped by the liposomes, determined following lysis 
of the liposome:siRNA complex.  
3.1.4 Ability of liposomes to protect siRNA from serum nucleases 
 Ultimately, liposomes must protect and deliver siRNA to target organs and cells 
in vivo. As mentioned previously, this includes protecting the siRNA payload against 
serum nucleases that can degrade the siRNA and destroy its antisense function. To test 
the ability of both non-targeting and folate-decorated liposomes to protect siRNA against 
serum nucleases, aliquots of liposome-siRNA synthesized using the “passive 
encapsulation” protocol were incubated in FBS in a 1: ratio (v/v) and separated using a 
15% acrylamide TBE-PAGE gel (Figure 4). The presence of bands indicates intact 
siRNA. Degraded siRNA was removed during siRNA purification; was of high 
electrophoretic mobility (due to small size of degradation products) and did not 
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Table 3.2. Quantification of liposome-siRNA interaction determined by the 
RiboGreen assay. Liposome-siRNA solutions were either treated with RiboGreen 
working solution alone (intact liposomes) or in the presence of 10% Triton X-100 (lysed 
liposomes). Lysed readings were used to determine the amount of siRNA on the interior 
of the liposomes and the combination of intact and lysed readings determined the total 
amount of siRNA entrapped. 
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 Lipoplex method Passive encapsulation 
method 
Percentage of total siRNA 
entrapped 
94.2 ± 9.5 49.4 ± 3.42 
Percentage of total siRNA 
encapsulated 
76.0 ± 8.1 43.7 ± 2.96 
Percentage of siRNA 
encapsulated after extrusion 
80.68 ± 2.90 86.05 ± 3.03 
 
 
 
 
 
 
 
 
 
61 
 
appear in the size range of intact siRNA; or was undetectable by ethidium bromide 
staining due to small size. Figure 3.4 indicates that both the non-targeting liposomes and 
the folate-decorated liposomes can protect siRNA up to 48 hours, while the naked siRNA 
begins to degrade at 4 h. This is a critical consideration to allow sufficient time for 
liposome:siRNA complexes to accumulate at tumour sites.  
3.2 Assessing folate-FR-mediated uptake in FR-expressing cell lines, and tissue/organ 
distribution following systemic administration in mice 
 3.2.1 FR expression in various cell lines and xenografts 
 To determine whether decorating liposomes with folate to target FR on cells 
enhances cellular uptake over non-targeting particles, the FR l (folate receptor 1) level on 
cells was first determined. Multiple cell lines were tested by incubating cells with a 
FOLR1 monoclonal antibody and subsequent secondary antibody conjugated to 
phycoerythrin (PE), which could be detected by flow cytometry (Figure 3.5). These data 
indicate that the KB cell line possessed the highest level of FR expression with >95% of 
cells showing FR positivity and a mean fluorescence intensity (MFI), a measure of the 
average fluorescent on a per cell basis, over fourfold higher than the cell line with the 
next highest FR MRI (HeLa). Both HeLa and OVCAR-3 cells displayed moderate FR 
levels, with approximately 50% of cells being FR-positive. A549 cells had the lowest FR 
level, with less than 5% cells of cells positive for FR and a negligible MFI. This wide 
spectrum of FR expression across the various cell lines provided a powerful diagnostic 
system to investigate the impact that targeting the FR had on cellular uptake. The high 
FR-expressing cell line KB (FR++)(Figure 3.5) was selected to investigate folate-FR 
mediated uptake. Because of the very low FR levels in A549 (FR-) cells (Figure 3.5), 
they were selected as a control for comparison to assess the capacity of FR status to 
predict differences in folate-mediated uptake of liposomally-encapsulated siRNA 
between cell lines, and provided a suitable negative control to account for factors 
independent of FR. The cell lines were evaluated for siRNA uptake in the presence of 
either folate-complete media or folate-depleted media (the latter induced by replacing 
folate-complete medium 3 hours prior to assessment, and the former maintained by  
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Figure 3.4. siRNA integrity following serum nuclease incubation. Non-targeting and 
folate-decorated liposome:siRNA complexes synthesized using the “passive 
encapsulation” method, or naked siRNA without liposomes, was incubated in a 1:1 (v/v) 
ratio for 1, 4, 8, 24, or 48 h. siRNA was then extracted from samples using the standard 
RNA extraction method and separated by electrophoresis in a 15% acrylamide TBE-
PAGE gel. The presence of bands indicates intact siRNA.  
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Figure 3.5. Folate receptor levels in various cell lines (determined by flow 
cytometry). Cells were cultured in 6 well plates for 24 hrs and then exposed to either 
folate-complete or folate-depleted media for 3 h prior to harvesting and incubation with 
FOLR1 monoclonal antibody. Next, the cells were incubated with PE-conjugated 
secondary antibody and analyzed for PE levels by flow cytometer.  
A) Histogram showing representative gating for all cell lines treated with FR primary 
antibody and KB cells treated with isotype (control) antibody  
B) Percentage of cells positive for FOLR1  
C) Mean fluorescence intensity (MFI) of cells (arbitrary value relating to average 
fluorescence on a per cell basis).  
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replacing medium with fresh medium 3 hours prior to assessment) to determine whether 
conditions where the amount of folate unassociated with liposomes would affect FR 
levels in target cells. The assessment was predicated on the possibility that that high 
unassociated folate in medium would reduce FR levels due to reduced cellular 
requirement for folate, and that low medium folate would result in increased cellular 
production of FR in response to increased requirement for folate.  However, there was no 
difference in FR level in cells induced by altering medium folate.   
 To test the tissue/organ distribution and silencing ability of FR-targeting 
liposomes in vivo, KB cells were inoculated into nude mice and grown as subcutaneous 
xenografts. Since cells are likely to have different characteristics in vivo than in vitro, FR 
level in KB xenografts was confirmed by immunoblot (Figure 3.6). In the data shown in 
that figure, KB and A549 cells grown in vitro were included as positive and negative FR 
expressers, respectively. KB xenografts and KB cells grown in vitro had similar levels of 
FR protein, while the A549 cells grown in vitro did not.  
3.2.2 Liposomes enhance siRNA uptake compared to naked siRNA and folate 
decoration further enhanced uptake in FR positive cells. 
 Non-targeting siRNA-loaded liposomes (i.e., no folate) were tested to determine 
if they facilitated cellular uptake of control, non-targeting siRNA (C2) compared to 
naked C2 siRNA alone (Figure 3.7). For in vivo purposes, it has been reported that 
PEGylating liposomes greatly enhances siRNA delivery by inhibiting RES entrapment
105
, 
so the effect of coating liposomes with PEG either directly in the lipid cake prior to 
extrusion (+PEG before) or after extrusion (+PEG after) was tested (Figure 3.7). The 
non-targeting liposomes showed a significant increase in uptake compared to naked 
siRNA (p<0.05) and the inclusion of PEG either before or after had no significant effect 
on uptake. 
The effect of decorating liposomes with folate to enhance cellular uptake in FR-
expressing cells was assessed (Figure 3.8). At first glance, and looking at only the FR-
positive KB cells (black bars), it would appear that folate decoration did enhance cellular 
uptake by 11.6%. However, there was an unexpected but similar increase (10.3%) in  
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Figure 3.6. FR protein expression of KB xenografts. KB cells were grown in culture 
and then inoculated in NIH-III nude mice. Upon reaching an average size of 600 mm
3
, 
mice were sacrificed and KB tumours were harvested for immunoblot. Cultured KB and 
A549 cells were also included as a reference. Actin protein levels were used as an 
internal control and run on a separate gel due to the non-reducing conditions required for 
FOLR1 antibody binding.  
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Figure 3.7. Percentage of cells positive for Cy3-siRNA after transfection with 
PEGylated liposomes or naked siRNA. Non-targeting liposomes encapsulating control, 
non-targeting siRNA (C2) were synthesized according to the “passive encapsulation” 
protocol and PEG was added either prior to or following extrusion. Liposomes were 
transfected in HeLa cells for 4 h before cells were harvested and assessed for siRNA 
uptake by flow cytometry. 
A) Histogram showing gating of HeLa cells treated with non-fol-Cy3-C2RNA (+PEG 
before). 94.6% HeLa cells positive for Cy3-siRNA uptake, 5.44% negative.  
B) Percentage of HeLa cells positive for Cy3 siRNA uptake using various delivery 
agents. 
Naked siRNA – siRNA transfected alone with no delivery agent 
non-fol-Cy3-C2RNA (-PEG) – non-targeting liposomes containing no PEG 
non-fol-Cy3-C2RNA (+PEG before) – PEG added directly to the lipid cake prior to 
extrusion 
non-fol-Cy3-C2RNA (+PEG after) - PEG added after extrusion. 
One experiment, n=3; *p<0.05 compared to naked siRNA. 
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Figure 3.8. Effect of liposome folate decoration on the cellular uptake of Cy3-siRNA. 
Non-targeting (no folate) and folate-decorated liposomes encapsulating Cy3-labeled 
control, non-targeting siRNA (C2) were synthesized according to the “passive 
encapsulation” protocol. Folate was added directly to the lipid film layer prior to 
extrusion. FR-positive (KB) and FR negative (A549) cell lines were grown in 6 well 
plates for 24 hours and treated with transfected for 4 h before being harvested for flow 
cytometry. 
A) Histogram showing gating of KB cells treated with fol-Cy3-C2RNA. 61.4% KB cells 
positive for Cy3-siRNA uptake, 38.6% negative.  
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents. non-
fol-Cy3-C2RNA – non-targeting liposomes 
fol-Cy3-C2RNA – folate decorated liposomes. 
One experiment, n = 3; *p<0.05 compared to naked siRNA in KB cells; 
&
p<0.05 
compared to naked siRNA in A549 cells 
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siRNA uptake mediated by folate decoration in FR-negative A549 cells (white bars). 
These data suggest that the increased uptake of siRNA encapsulated in folate-decorated 
liposomes was due to an FR-independent event (possibly mediated by differences in 
particle surface charge or the amount of siRNA that was incorporated following 
synthesis, since differences can occur among batches).   
 The next step was to increase the amount of folate added to the liposomes to 
determine whether increasing targeting moieties revealed differences in uptake between 
cells with low and high FR. Non-targeting, folate-decorated liposomes with the original 
amount of folate added (0.81 nmol) and folate decorated liposomes with 3 times more 
folate added to the lipid layer (2.42 nmol) were used to treat KB and A549 cells (Figure 
3.9). In the KB cell line, the presence of folate on liposomes decreased the fraction of 
cells positive for siRNA uptake. In addition, increasing the amount of folate used to 
decorate siRNA-containing liposomes further decreased the fraction of cells positive for 
siRNA uptake after treatment with those liposomes (Figure 3.9B). The decreased siRNA 
uptake may be at least partly attributable to decreased encapsulation of siRNA in 
complexes treated with folate: Cy3 siRNA is red in colour, and folate-decorated 
liposome:siRNA complexes were visibly less intensely coloured in solution than 
liposome:siRNA complexes without folate (data not shown), suggesting that less Cy3-
siRNA was entrapped in folated liposomes. This was theoretically possible, since 
negative charge would be increased in DSPE molecules associated with folate and that 
negative charge might repel similarly negatively-charged siRNA. Regardless of the 
delivery agent, A549 cells all had >98% of cells positive for Cy3-siRNA uptake, 
suggesting that too high a concentration of liposomes was being used to allow 
identification of differences in uptake mediated by FR (Figure 3.9B, white bars). This 
was further exemplified when treatment with either non-targeting (i.e., no folate) or 
folate-decorated liposomes resulted in >80% and >95% of cells being Cy3-siRNA 
positive in KB and A549 cells, respectively (Figure 3.10). The high level of siRNA 
uptake, as seen is the large peak shift in Figure 10A, was unusual. When DOTAP sources 
were investigated it was apparent that the DOTAP used to generate the liposomes was 
concentrated to a degree much higher than manufacturer specifications and, therefore, 
had increased the overall positivity of the liposomes. The increased positivity would have  
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Figure 3.9. Effect of increasing liposome folate decoration on the cellular uptake of 
Cy3-siRNA. Non-folated and folate-decorated liposomes were synthesized according to 
the “passive encapsulation” protocol. Folate was added directly to the lipid film layer 
prior to extrusion. FR positive (KB) and FR negative (A549) cell lines were grown in 6 
well plates for 24 hours and transfected for 4 h before being harvested for flow 
cytometry. 
A) Histogram showing gating of KB cells treated with fol(3X)-Cy3-C2RNA. 74.2% KB 
cells positive for Cy3-siRNA uptake, 25.8% negative.  
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents. 
non-fol-Cy3-C2RNA – non-targeting liposomes 
fol(1X)-Cy3-C2RNA – folate decorated liposomes 
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added 
One experiment, n = 3. 
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Figure 3.10. Effect of high DOTAP concentration on the cellular uptake of Cy3-
siRNA. Non-folated and folate-decorated liposomes were synthesized according to the 
“passive encapsulation” protocol. Folate was added directly to the lipid film layer prior to 
extrusion. FR positive (KB) and FR negative (A549) cell lines were grown in 6 well 
plates for 24 hours and transfected for 4 h before being harvested for flow cytometry. 
A) Histogram showing gating of an individual A549 sample treated with fol(1X)-Cy3-
C2RNA. 99.9% A549 cells positive for Cy3-siRNA uptake, 0.113% negative.  
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents.  
non-fol-Cy3-C2RNA – non-folated, non-targeting liposomes 
fol(1X)-Cy3-C2RNA – folate-decorated liposomes 
fol(3X)-Cy3-C2RNA – folate-decorated liposomes with 3 times as much folate added as to 
fol(1X)-Cy3-C2RNA.  
One representative experiment of several, n = 3. 
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been expected to increase non-specific uptake of all liposomes, regardless of folate status, 
due to strong interaction with negatively-charged plasma membranes. A fresh batch of 
DOTAP was purchased and used in future experiments.  
 In addition to the issue of DOTAP concentration, there remained the observation 
that no difference in cellular uptake of liposome-encapsulated siRNA between non-
folated and folate-decorated liposomes in the FR-positive KB cell line (Figure 3.8). 
Literature reports indicate that the majority of folate added to medium surrounding FR-
expressing cells is taken up within the first hour of addition and then plateaus
130,131
. 
Therefore, to assess whether addition of folate to liposomes increased uptake into FR-
positive cells in a time-dependent fashion, uptake at earlier times was tested (Figure 
3.11). In accord with published reports
130,131
, folate-decorated liposomes, especially when 
folate was added after the extrusion process, were taken up by FR-positive KB cells as 
soon as 30 m after addition and continued to be taken up by cells up to 2 h after addition. 
Non-folated liposomes delivered siRNA to less than 10% of KB cells up to the 1 h after 
addition, although approximately 30% of cells received siRNA by 2 h post-addition. This 
suggests that the greatest difference in uptake between non-targeting and folate-decorated 
liposomes might be achieved within the first hour of addition of liposomes to cells. All 
subsequent experiments were performed with a transfection time of 30 m. In addition, 
increasing the amount of folate by addition of folate directly to the lipid film layer before 
extrusion reduced Cy3 siRNA uptake (Figure 3.9B). On the other hand, increasing the 
amount of folate after extrusion increased Cy3 siRNA uptake (Figure 3.11B). These data 
suggest that post-extrusion incubation with folate is desirable as a folate-decoration 
strategy. 
To further explore addition of folate after liposome extrusion as a strategy to 
increase uptake of liposome-encapsulated siRNA, a partial repeat of Figure 3.11B was 
carried out with the desired treatment groups. Non-folated liposomes and liposomes 
prepared using two concentrations of folate added after liposome extrusion were 
generated. They were then added to FR-positive KB cells for 30 minutes and siRNA 
uptake into those cells was assessed (Figure 3.12). The addition of folate following the  
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Figure 3.11. Effect of incubation time on the cellular uptake of liposome:Cy3-siRNA 
complexes into FR-positive KB cells. Non-folated and folate-decorated liposomes were 
synthesized according to the “passive encapsulation” protocol. FR-positive KB cells were 
grown in 6 well plates for 24 hours and incubated with liposome:siRNA complexes (C2: 
non-targeting scrambled control siRNA) for 30 m, 1 h, or 2 h before being harvested for 
flow cytometry. 
A) Histogram showing gating of an individual KB sample treated with fol(1X)-Cy3-
C2RNA (after) at 30 m. 70.2% KB cells positive for Cy3-siRNA uptake, 29.8% negative.  
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents.  
non-fol-Cy3-C2RNA – non-targeting liposomes 
fol(1X)-Cy3-C2RNA (before) – folate added to lipid film layer prior to extrusion 
fol(1X)-Cy3-C2RNA (after)– folate added following the extrusion process 
fol(3X)-Cy3-C2RNA (after)–3X the amount of folate added following the extrusion 
process. 
One experiment, n = 3. 
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Figure 3.12. Effect of increasing liposome folate decoration following extrusion on 
the cellular uptake of Cy3-siRNA. Non-folated and folate-decorated liposome:siRNA 
complexes were synthesized according to the “passive encapsulation” protocol. Folate 
was incubated with liposomes for >1 h following extrusion. FR-positive (KB) cells were 
grown in 6 well plates for 24 hours and transfected for 30 m before being harvested for 
flow cytometric analysis of Cy3-labeled siRNA uptake. 
A) Histogram showing gating of an individual KB sample treated with fol(3X)-Cy3-
C2RNA. 72.9% KB cells positive for Cy3-siRNA uptake, 27.1% negative.  
B) Percentage of cells positive for Cy3 siRNA using various delivery agents 
non-fol-Cy3-C2RNA – non-targeting liposomes 
fol(1X)-Cy3-C2RNA – folate decorated liposomes 
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added 
Two experiments, n = 6 
*p<0.05 compared to non-fol-Cy3-C2RNA 
**p<0.05 compared to fol(1X)-Cy3-C2RNA 
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extrusion process increased the percentage of KB cells positive for Cy3 siRNA by ~30% 
and increasing the amount of folate added to the liposomes by 3X further enhanced Cy3-
siRNA positivity by another ~20%. To take the analysis further, and to assess whether 
liposomes prepared with folate added after extrusion would target siRNA delivery to FR-
positive cells more effectively than to FR-negative cells, a wider range of folate 
concentrations were added to liposome aliquots following extrusion and the resulting 
folated liposome:siRNA complexes added to both FR-positive KB and FR-negative A549 
cells (Figure 3.13). Figures 13A and 13B are different representations of the same data 
for ease of comparison either within the same cell line or between the two, respectively. 
Decorating the liposomes with folate significantly increased Cy3 siRNA uptake in both 
KB and A549 cells (Figure 3.13A). However, the increase was greater in the FR positive 
KB cell line at all folate concentrations (Figure 3.13B). Furthermore, increasing the 
amount of folate added to the liposomes up to 6 times more than the initial level of added 
folate enhanced Cy3 siRNA uptake in a folate concentration-dependent manner, while 
increasing the amount of folate from 1X to 6X did not increase siRNA uptake in the FR-
negative A549 cell line (Figure 3.13A).  
3.2.3 Non-targeting and folate decorated liposome tissue/organ distribution 
following systemic administration in nude mice. 
To complement the in vitro uptake data, the biodistribution of the liposome 
particles was assessed after tail vein (systemic) administration. An amount of 0.035:50 
molar mass DOTAP:Cy3-C2RNA liposome/siRNA mixture (5 nmol siRNA per injection 
prior to extrusion) was injected into nude mice and, after 6 h, mice were sacrificed for 
tissue collection. The KB tumours (Figure 3.14a) and liver, spleen, connective tissue 
(surrounding tumour), kidney, and muscle (Figure 3.14b) were removed and placed in 
plastic cassettes containing O.C.T for cryosectioning. The samples were then cut into 10 
μm thick sections and photographed immediately using a fluorescence microscope. There 
was limited fluorescence in both the non-folated and folate-decorated liposome treated 
KB xenografts. Subjectively, KB tumours treated with the non-targeting liposome may 
have a higher Cy3 siRNA fluorescence than tumours treated with the folate-decorated 
liposomes (Figure 3.14A). However, this cannot be quantified due to a lack of overall  
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Figure 3.13. Effect of increasing folate concentrations used to functionalize 
liposomes after extrusion on cellular uptake of Cy3-siRNA. Non-folated and folate-
decorated liposomes were synthesized according to the “passive encapsulation” protocol. 
Folate was incubated with liposomes for >1 h following extrusion. FR-positive (KB) and 
FR-negative (A549) cells were grown in 6 well plates for 24 hours and treated with 
siRNA:liposomal preparations for 30 min before being harvested for flow cytometric 
analysis of siRNA uptake. 
A) Histogram showing gating of an individual KB sample treated with fol(10X)-Cy3-
C2RNA. 75.9% KB cells positive for Cy3-siRNA uptake, 24.1% negative.  
B) Bar graph of percentage of cells positive for Cy3 siRNA using range of folate 
concentrations added after extrusion to compare within same cell lines 
C) Line graph showing percentage of cells positive for Cy3 siRNA after treatment with 
liposomes prepared using a range of folate concentrations added after extrusion to 
compare between cell lines (different representation of same data in B) 
non-fol-Cy3-C2RNA – non-targeting liposomes 
fol(1X)-Cy3-C2RNA – folate decorated liposomes 
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added 
fol(6X)-Cy3-C2RNA – folate decorated liposomes with 6X as much folate added 
fol(10X)-Cy3-C2RNA – folate decorated liposomes with 10X as much folate added. 
Two experiments, n = 6 
A: p<0.05 compared to non-fol-Cy3-C2RNA in KB cells 
B: p<0.05 compared to fol(1X)-Cy3-C2RNA in KB cells 
C: p<0.05 compared to fol(3X)-Cy3-C2RNA in KB cells 
D: p<0.05 compared to non-fol-Cy3-C2RNA in A549 cells 
*: p<0.05 compared to corresponding folate concentrations in A549 cells 
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Figure 3.14. Tissue/organ distribution of non-targeting and folate decorated 
liposomes containing Cy3 siRNA. Mice were inoculated with 2 million KB cells 
(Section 2.16) and euthanized on day 27. Six h prior to euthanasia, mice were 
systemically (tail vein) injected with 0.035:50 molar mass DOTAP:Cy3-C2RNA 
liposome/siRNA mixture (5 nmol siRNA per injection prior to extrusion). KB xenografts 
and tissues were harvested from similar areas on each mouse and placed in a plastic 
cassette containing OCT (freezing media). The samples were then frozen at -80
o
C and cut 
in 10 μm sections for fluorescence microscopy to visualize fluorescent Cy3 C2 siRNA 
accumulated in tissues. 
A) Representative images of KB xenograft tumours in 3 of the mice per treatment 
group 
B) Representative images of selected tissues from the organs of a selected mouse 
(only one used as fluorescence patterns were similar across mice) 
6 mice per treatment group. 
Magnification 100X 
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fluorescence observed within individual images and variability between imaged sections 
(some sections displayed no fluorescence). The other organs with the highest 
fluorescence were the liver and spleen, which is expected because organs in the 
reticuloendothelial system preferentially accumulate systemically injected 
nanoparticles
60
. Unexpectedly, fluorescence was only observed in muscle treated with 
non-targeting liposomes, which may have only been an artifact of the non-targeting 
treatment group containing a higher initial concentration of Cy3-siRNA. Images were 
also taken of the kidney, where cationic liposomes have been know to accumulate
132
. 
However, due to autofluorescence from the tissue itself, no fluorescence attributable to 
Cy3 siRNA accumulation could be confirmed (data not shown). 
3.3 Ability of liposome:targeting siRNA complexes to knock down a gene target 
 3.3.1 Antisense effect of liposomes delivering TS siRNA payload in vitro 
 Before testing the liposome formulations for their ability to effectively 
downregulate TS transcript levels, the functionality of the TS siRNA (TSRNA) in KB 
and A549 cells (both of which express TS) was verified using a proven commercial 
liposomal delivery system (Lipofectamine 2000)(Figure 3.15). As reported previously 
using this anti-TS siRNA in A549 and other cell lines
28
, TS transcript levels were 
reduced by ~80%. TS knockdown in KB cells is shown for the first time.  
Measurement of TS mRNA before and after treatment with liposome:siRNA 
complexes indicated that the liposomes were not able to downregulate TS mRNA levels 
24 hours after addition of complexes (results not shown and Figure 3.16). The use of 
PEG in liposomes, although desirable to increase liposome:siRNA time in circulation 
time and to inhibits RES entrapment, might also abrogate siRNA- mediated mRNA 
degradation by preventing escape of internalized siRNAs from endosomes
60
. To assess 
possible PEG inhibition of siRNA activity, both PEGylated and non-PEGylated 
liposomes were formulated and tested for their silencing ability in KB and A549 cell lines 
at 24 h post-addition (Figure 3.16). Neither PEGylated nor non-PEGylated liposomes 
were able to downregulate TS mRNA levels in either of the cell lines. To confirm that the 
liposome:siRNA complexes were capable of entering cells , fluorescent images were  
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Figure 3.15. Relative quantity of TS mRNA transcript s following treatment with TS 
siRNA delivered using Lipofectamine 2000 (LF2K). KB and A549 cells were grown in 
6 well plates for 24 h. Cells were then transfected with TS siRNA for 4 h using LF2K. 
Fresh media was added to the wells and 24 h later the cells were harvested for 
measurement of TS mRNA (GAPDH used as endogenous control) by qPCR. 
LF2K C2RNA – transfected with LF2K containing 10 nM control siRNA 
LF2K TSRNA – transfected with LF2K containing 5 nM control siRNA and 5 nM TS 
RNA 
One experiment, n = 3.  
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Figure 3.16. TS mRNA transcript levels following treatment with PEGylated and 
non-PEGylated liposomes. Non-folated and folate-decorated liposome:siRNA 
complexes were synthesized according to the “passive encapsulation” protocol. The 
PEGylated liposomes were then coated with DSPE-PEG. KB and A549 cells were grown 
in 6 well plates for 24 h. Cells were then treated with treated with complexes for 4 h. 24 h 
later the cells were harvested for real-time PCR. 
A) TS mRNA levels in KB cells 
B) TS mRNA levels in A549 cells 
non-fol-Cy3-C2RNA (+PEG) – non-targeting liposomes containing control siRNA and 
coated with PEG 
non-fol-Cy3-C2RNA (+PEG) – non-targeting liposomes containing control siRNA and 
no PEG on surface 
non-fol-Cy3-TSRNA (+PEG) – non-targeting liposomes containing TS siRNA and 
coated with PEG 
non-fol-Cy3-TSRNA (+PEG) – non-targeting liposomes containing TS siRNA and no 
PEG on surface 
fol-Cy3-C2RNA (+PEG) – folate decorated liposomes containing control siRNA and 
coated with PEG 
fol-Cy3-C2RNA (+PEG) – folate decorated liposomes containing control siRNA and no 
PEG on surface 
fol-Cy3-TSRNA (+PEG) – folate decorated liposomes containing TS siRNA and coated 
with PEG 
fol-Cy3-TSRNA (+PEG) – folate decorated liposomes containing TS siRNA and no PEG 
on surface 
One experiment, n = 2.  
 
 
 
97 
 
A 
 
 
   
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
98 
 
taken 24 h following transfection (Figure 3.17). The liposomes used were non-PEGylated 
in order to maximize uptake and increase potential to downregulate TS. From the images, 
it is evident that the cells took up a significant amount of Cy3-TS siRNA. To confirm that 
siRNA was not confined to target cell surfaces without entry into cell interior, several 
samples were analyzed by confocal microscopy through several planes. Confocal images 
confirmed that siRNAs were present in cytoplasm (data not shown).  
Knowing that the siRNA delivered using liposomes entered target cells, it was 
possible that endocytosed liposome:Cy3 siRNA particles required longer than 24 h to 
escape the endosomal compartment and enter cytoplasm and interact productively with 
RISC complexes. Therefore, cells were harvested 48 h after siRNA: liposome complex 
addition and assessed for TS mRNA knockdown by qPCR (Figure 3.18b). Additionally, 
and in order to promote endosomal escape, the liposomes were synthesized with higher 
degrees of DOTAP (increased positivity) and the fusogenic lipid DOPE was added (see 
end of Section 2.1 in Introduction for discussion of factors affecting endosomal escape). 
The presence of protamine was also investigated to determine whether the stable complex 
it formed with the siRNA might interfere with siRNA activity (Figure 3.18). Only non-
targeted liposomes were synthesized in an attempt to generate TS downregulation of any 
degree before using reagents to make targeted liposomes. No significant reduction in TS 
mRNA levels was observed after treatment with any of the liposome formulations at 
either 24 or 48 hours. Although treatment with TS siRNA:liposome formulations 
containing 4X DOTAP and DOPE resulted in TS mRNA levels that trended to decrease, 
that did not induce significant differences. It is possible that increasing the positivity and 
amount of DOPE used to generate liposomes might be a fruitful strategy to lead to target 
mRNA knockdown. 
 3.3.2 Antisense effect of liposomes delivering TS siRNA payload in vivo 
The formulated liposomes were unable to downregulate TS mRNA levels in vitro. 
However, circumstances in vivo are different. Therefore, and while assessing the 
biodistribution of liposomes in vivo, TS mRNA levels in KB tumour xenografts were 
analyzed following a 4 week treatment course where liposome:Cy3 siRNA complexes  
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Figure 3.17. Fluorescent images of KB cells transfected with liposome/Cy3-siRNA. 
Non-folated and folate-decorated liposome:siRNA complexes were synthesized 
according to the “passive encapsulation” protocol. KB cells were cultured for 24 h in 6 
well plates and then transfected for 4 h to maximize uptake. 24 h later the cells were 
washed 2X with PBS to remove any excess liposome:siRNA. The cells and siRNA 
uptake were then imaged by fluorescence microscopy. The blue background in the 
overlay images is an artifact generated by the computer program software.  
Magnification 200X 
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Figure 3.18. TS mRNA transcript levels 24 and 48 h after treatment with various 
liposomal formulations. Non-folated liposome:siRNA complexes were synthesized 
according to the “passive encapsulation” protocol. KB cells were grown in 6 well plates 
for 24 h. Cells were then treated with complexes for 4 h. 24 or 48 h later the cells were 
harvested for real-time PCR. 
A) TS mRNA levels in KB cells 24 h after transfection 
B) TS mRNA levels in KB cells 48 h after transfection 
DOT 2X C2RNA (+prot) – liposomes with 2X the amount of DOTAP included carrying 
control siRNA complexed with protamine 
DOT 2X TSRNA (+prot) – liposomes with 2X the amount of DOTAP included carrying 
TS siRNA complexed with protamine 
DOT 2X C2RNA (-prot) – liposomes with 2X the amount of DOTAP included carrying 
control siRNA with no protamine 
DOT 2X TSRNA (-prot) – liposomes with 2X the amount of DOTAP included carrying 
TS siRNA with no protamine 
DOT 2X, DOPE C2RNA (+prot) – liposomes with 2X the amount of DOTAP and DOPE 
included carrying control siRNA complexed with protamine 
DOT 2X TSRNA (+prot) – liposomes with 2X the amount of DOTAP and DOPE 
included carrying TS siRNA complexed with protamine 
DOT 4X C2RNA (+prot) – liposomes with 4X the amount of DOTAP included carrying 
control siRNA complexed with protamine 
DOT 4X TSRNA (+prot) – liposomes with 4X the amount of DOTAP included carrying 
TS siRNA complexed with protamine 
LF2K C2RNA – transfected with LF2K containing 10 nM control siRNA 
LF2K TSRNA – transfected with LF2K containing 5 nM control siRNA and 5 nM TS 
RNA. 
One experiment, n = 2.  
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were injected twice per week in mouse tail veins. The mice were then sacrificed on day 
27 and the KB xenografts were harvested for RNA isolation and qPCR (Figure 3.19). 
Similar to the results seen in vitro, no TS downregulation was observed in any of the 
treatment groups in vivo.  The lack of downregulation would have likely been further 
compounded by the limited uptake in tumour tissue as observed in the biodistribution 
study (Figure 3.14A).  
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Figure 3.19. TS mRNA levels in KB xenografts from nude mice following systemic 
liposome:Cy3 TS siRNA administration. Mice were inoculated at 2 sites with 2 million 
KB cells and sacrificed on day 27. Mice were systemically injected (tail vein) with 
0.035:50 molar mass DOTAP:Cy3-TSRNA liposome:siRNA complexes once per week 
for 4 weeks. KB xenografts were harvested from each mouse and frozen at-80
o
C. 
Sections of tumour were thawed and RNA was isolated for qPCR analysis of TS mRNA 
levels (GAPDH used as endogenous control). 
non-fol-Cy3-TSRNA – non-targeting liposomes containing TS siRNA 
fol-Cy3-C2RNA – folate decorated liposomes containing TS siRNA 
fol-Cy3-TSRNA – folate decorated liposomes containing TS siRNA. 
6 mice per treatment group, 2 tumours per mouse. 
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Chapter 4  
4 Discussion 
The purpose of this work was to assess the ability of folate functionalized 
liposomes to deliver TS siRNA to the RNAi machinery of FR-positive cancer cells to 
activate its antisense effect.  We initially hypothesized that our non-targeting liposomes 
will facilitate siRNA uptake into cells more efficiently than naked siRNA alone.  
Subsequently, decoration of liposomes with folate ligand will enhance their ability to 
deliver siRNA to FR-positive human tumour cells both in vitro and in vivo as a method to 
increase antisense activity over non-targeting vehicles.  In this section I will discuss 
implications of the physical attributes of the liposome particles [Section 4.1: particle 
charge and size (Section 4.1.1), levels of folate decoration (Section 4.1.2), siRNA 
encapsulation yields (Section 4.1.3), serum nuclease protection (Section 4.1.4)]; analysis 
of cellular uptake and biodistribution studies [Section 4.2: choice of cells lines (Section 
4.2.1), troubleshooting lack of FR-mediated enhancement of uptake (Section 4.2.2)]; and 
challenges faced with TS mRNA transcript knockdown (Section 4.3).               
4.1 Implications of liposome physical characteristics 
4.1.1 Measurements of particle charge and size  
The non-targeting and folate decorated liposomes were determined to have zeta 
potentials in the range of 30-35 mV and diameters spanning from 130-150 nm. These 
values have varying implications depending on whether in vitro or in vivo liposome 
uptake and cargo delivery is being optimized. For example, in vitro, a higher positive zeta 
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potential or surface charge usually equates with higher cellular uptake
133,134
 and greater 
toxicities
135
 due to interactions with the negatively-charged plasma membrane on cells. In 
an in vivo setting, liposomes with an increased positive charge have been reported to 
correlate with enhanced accumulation in the liver: a consequence that may be 
undesirable, depending on the where delivery is desired (in this case, undesirable because 
delivery to tumour and not liver is the goal). However, and even with increased liver 
uptake, increased positive charge on liposomes has been shown to enhance uptake by 
tumour vasculature compared to neutral or anionic liposomes
132,136
. This correlates with 
the in vivo biodistribution of positively-charged liposomes I observed, because the 
highest amount of Cy3 siRNA fluorescence could be seen in the liver tissue (Figure 
3.14B). Particles with zeta potentials greater than 30 mV are considered strongly cationic 
and this strength of electrostatic repulsion has been linked to greater stability over time 
and resistance to the tendency of particles to aggregate over time and increase in size
137
. 
In fact, the data showing liposome stability over time is positive and encouraging. The 
liposomes remained stable up to 6 h and had begun to aggregate only 12 h after synthesis 
(Figure 3.2C). Remaining stable in solution for longer than a few hours was critical to 
ensuring that aggregation did not taken place from the time of synthesis to the time of 
addition to cells in culture or tail vein injection into whole animals: an interval likely to 
be several hours under normal circumstances. On the other hand, if the particles are too 
stable it can prevent siRNA release into the cytosol once taken up by the cell
138
. 
There is some debate as to the size of liposomes for optimal delivery to tumour 
tissue. Some researchers believe particles should be less than 100 nm
104
, while others 
would argue a diameter less than 200 nm is sufficient for effective in vivo delivery
133,139
. 
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Sizes over 200 nm have been shown to switch from a clathrin-dependent mechanism of 
endocystosis to a caveolae-dependent uptake mechanism, and this could influence 
cellular uptake depending on mechanisms available in target cell populations
140
. In 
addition, the maximum size of particles capable of escaping leaky tumour vasculature 
varies depending on tumour type, but typically falls somewhere in the range of 200-600 
nm
141,142
. Particles larger than this size would have a difficult time taking advantage of 
the EPR effect to accumulate at the tumour environment (see Section 1.6 for further 
explanation of EPR effect and challenges of delivery). Therefore, the non-targeting and 
folate-decorated liposomes fall within a size range that should allow for effective use 
both in vitro and in vivo. However, it will be important to conduct an in vivo study 
comparing the biodistribution of current liposomes versus those of smaller size resulting 
from further extrusion using 50 nm pores.  
4.1.2 Low folate insertion in liposomes 
It was surprising that less than 10% of the DSPE-PEG-folate that was added to the 
liposomes either before extrusion or after was inserted in the liposomes (Section 3.1.2). 
Some research groups have reported between 60-90% folate insertion with their post-
insertion techniques
143-145
. If 100% of the DSPE-PEG-folate was inserted into liposomes, 
then the folate-decorated liposomes would have an overall folate mol% of 0.23, meaning 
the actual folate mol% < 0.023% for the liposomes containing the standard amount of 
folate (fol(1X)) since less than 10% insertion was observed (Section 3.1.2).  This amount 
of inserted DSPE-folate-PEG is considerably lower than typically used. However, one 
study reported optimal cellular uptake with liposomes bearing as low as 0.03% fol 
mol%
146
. The low amount of incorporated folate may be one reason that folate-decoration 
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of liposomes did not enhance uptake in FR-positive KB cells compared to the FR-
negative A549 cells (Figure 3.8) unless the amount of folate added following liposome 
extrusion was increased (Figures 3.12 & 3.13). Regardless, from data reported in the 
literature
144,147
 and experience gained in the course of these studies, inserting the folate 
following extrusion allows for better control and folate decoration exclusively on the 
outside of the liposome (rather than both in the interior and on the exterior), compared to 
adding it directly to the lipid layer. Direct addition of folate to the lipid prior to exclusion 
results in folate incorporation roughly equally on the exterior and in the interior of the 
lipid bilayer, thus reducing the amount of exterior folate available for binding to target 
cell folate receptors
147
. 
4.1.3 Assessing siRNA encapsulation yield 
Using the passive encapsulation protocol for liposome synthesis, generally 3-40% 
of antisense molecules will become encapsulated depending on the lipid constituents and 
overall charge of the particles
148-150
. Incorporation of 100% of siRNA in the interior 
would be unexpected because, theoretically, 50% of siRNA molecules should attach to 
the interior of the liposome as it forms and 50% should interact with the exterior. In 
addition, the extrusion process is relatively inefficient at associating siRNA with 
liposomes, as evidenced by pink colouring on filters (due to the pink colour of Cy3 
siRNA visible to the naked eye) after extrusion (subjective observation, data not shown). 
Therefore, a roughly 44% siRNA encapsulation percentage as indicated by the 
RiboGreen assay (Table 3.2) is relatively successful in terms of siRNA:liposome 
association. However, due to certain limitations of the RiboGreen assay (discussed 
above) the degree of association may be overestimated. Regardless, a higher percentage 
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of siRNA in liposomes achieved using this method, compared to other passive 
encapsulation methods, is not unexpected as the liposomes have a strong cationic charge. 
That charge would facilitate electrostatic interactions with the negatively charged siRNA. 
4.1.4 Prolonged protection of siRNA against serum nucleases 
The ability of both the non-targeting and folate decorated liposomes to protect 
siRNA from nuclease degradation up to 48 h was significant for two reasons. First, 
systemically-injected liposomes must pass though circulation before reaching their target 
tissues, so siRNA degradation soon after exposure to serum would render the therapy 
ineffective. Second, in many cases it can take anywhere from 12-24 h for liposome 
particles to reach and accumulate in the tumour microenvironment, and siRNA protection 
from nucleases remains essential during the period of time after arrival at target tissues 
and uptake into target cells
151,152
. 
4.2 Folate decoration on uptake and biodistribution studies 
 4.2.1 Choice of cell lines  
It has become common practice in testing the efficacy of folate-ligated particles to 
use the FR-positive KB cell line as well as a low FR-expressing cell line, such as 
A549
145,153,154
. The presence of the low FR expressing cell line, A549, helped to 
determine whether cell-specific, FR-independent differences in uptake between the 
targeting and folate-decorated liposomes are important considerations that would 
otherwise have been overlooked if only the FR-positive KB cells were used to determine 
differences in uptake between folate-positive and folate-negative liposomes. FR 
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expression was also measured in cells exposed to folate-depleted media for 3 h prior to 
exposure to siRNA:liposome preparations, to ensure that their FR levels were not 
upregulated by lack of folate (a possible cellular response to low folate). Upregulation 
would not have been expected during this very short time, but an increase in FR levels of 
over tenfold has been reported within 24 hours of folate depletion
155
. 
 4.2.2 Troubleshooting enhancement of FR-mediated uptake 
One of the two greatest challenges with this project was achieving an enhanced 
uptake in the FR-positive KB cells when exposed to folate-decorated liposomes, 
compared to non-folated non-targeting liposomes. The first major breakthrough on this 
front came when the liposome exposure time was reduced. The literature indicated that 
FR-mediated endocytosis occurs primarily within the first hour of exposure to 
liposomes
130,131
, while the non-specific uptake of cationic liposomes still increases past 4 
hours
156
. This is likely due to FR-mediated uptake being an active process versus passive 
general endocytosis. Since reducing the time to 30 minutes enhanced the difference in 
uptake between the folate-decorated and non-folated non-targeting liposomes (Figure 
3.11) it is hypothesized that part of the lack of enhancement seen previously (Figures 3.8 
& 3.9) may have been due to the non-targeting liposomes and/or both non-targeting and 
targeting liposomes reaching maximal uptake at some point during a 4 hour period of 
exposure to cells (i.e., a "plateau" effect obscuring differences that would have been 
evident before plateaus are reached). Furthermore, it was encouraging to see that 
increasing the amount of folate added to the liposomes increased cellular uptake in the 
KB cells, but not in the A549 cells (Figure 3.13), similar to reports of others
154,157
. 
Additionally, decorating the liposomes with any amount of folate caused a greater 
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increase in uptake in the KB (~40%) cells than compared to the A549 cells (~10%). The 
observed 10% increased in uptake of the folate decorated liposomes in FR-negative A549 
cells further reinforces the usefulness of the strategy of including a negative control in the 
experiment, as it is likely that folate decoration also enhances uptake to some degree via a 
non-FR-mediated interaction (e.g., steric hindrance, surface charge).  
As mentioned previously, cationic liposomes have been shown to preferentially 
accumulate in the liver
132,158
. It was unsurprising, then, that the biodistribution study 
revealed an abundance of Cy3 siRNA fluorescence in the biopsied liver tissue (Figure 
3.14B). Cationic liposomes also have a propensity to localize in the spleen, especially 
after saturating the liver, which is expected as these are the major players of the RES 
system
132,159
. Indeed, the results reported here are consistent with that. Unfortunately, 
there did not appear to be a higher fluorescence of Cy3 siRNA delivered by folate-
decorated liposomes to the FR-positive KB tumours compared to delivery by non-
targeting liposomes. In fact, the tumours in animals treated with siRNA-containing but 
non-folated (non-targeting) liposomes may have accumulated a larger amount of siRNA 
(with subjectively-assessed higher fluorescence overall)(Figure 3.14A). However, if true, 
this could also be due to slightly higher amounts of Cy3 siRNA loaded into the non-
folated liposomes (compared to folated liposomes), although they were prepared side by 
side and under identical conditions. Another possible factor contributing to lack of 
differences in accumulation of non-folated and folate-decorated liposomes in tumours 
could be the amount of folate ligand exposed on the liposomes and available for binding 
to receptors. The data from the in vitro uptake studies showed that uptake increased in 
FR-positive KB cells when folate decoration was increased post extrusion (Figures 3.12 
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& 3.13). On the other hand, the in vivo biodistribution study was performed with 
liposomes where folate was inserted directly into the lipid film layer prior to extrusion, 
meaning that less folate would have accumulated on the outside of the liposome and been 
available for binding. Several studies indicate that decorating particles with a targeting 
ligand does not increase accumulation of liposomal cargo molecules in the tumour 
environment, compared to similar non-targeting particles. However, targeting does 
increase active uptake in tumour cells themselves, which helps to overcome inhibition of 
non-specific endocytosis due to the EPR effect. As a result, one would expect to see non-
targeting liposomes accumulate in the interstitium and connective tissue surrounding the 
tumour and more targeted liposomes penetrating the actual tumour
152,160
. Therefore, 
assuming that folate decoration was low on the targeting liposomes, it is not surprising to 
see the non-targeting liposomes accumulate in tumour tissues to the same extent as their 
targeting counterparts (Figure 3.14A). At the same time it was disappointing that no 
fluorescence was observed in the connective tissue in close proximity to the tumour, 
which likely has more to do with a low overall amount of liposome/Cy3 siRNA that 
reached the tumour area.                
4.3 Challenges of achieving an antisense effect (transcript knockdown) in cells 
The second major obstacle faced in this project was the inability of the non-
targeting or folate decorated liposomes to achieve TS transcript downregulation both in 
vitro and in vivo. Initially, the thought was that a new batch of Cy3 TS siRNA obtained 
from Dharmacon might have an incorrect, non-complementary sequence. However, 
testing with a commercially-available transfection reagent (Lipofectamine 2000) 
indicated that the siRNA was able to downregulate TS mRNA in A549 cells when not 
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encapsulated in the liposomes tested in this study (Figure 3.15). Another possibility was 
that temperature fluctuations between 50-70
o
C during the extrusion process could have 
degraded the siRNA and rendered it ineffective, but non-modified siRNA has been 
shown to maintain its integrity and function after exposure to temperatures reaching 95
o
C 
and after temperature cycling from low to high
161
. As mentioned previously, the 
incorporation of PEG, while useful, can also impede endosomal escape
60
. Therefore, non-
PEGylated liposomes were synthesized in an attempt to maximize the potential for TS 
mRNA downregulation. The absence of PEG, however, did not result in a reduction in 
TS transcript levels in cells treated with siRNA:liposomes. We also varied the time 
between exposure of cells to targeting siRNA:liposome preparations and harvesting the 
cells for qPCR, based on the hypothesis that a longer time for liposomes to achieve 
endosomal escape to release siRNA payload into cytoplasm, but this modification did not 
result in siRNA effectiveness. It appears, from fluorescent microscope images, as though 
a great deal of siRNA had been taken up by the cell and, in some cases, the fluorescence 
pattern was punctate, suggesting containment in endosomes
162-164
 (Figure 3.17). A 
punctate pattern is not completely diagnostic of endosomal entrapment, however, and 
cannot be considered sufficiently strong evidence that this is the actual cause for lack of 
transcript downregulation. While not statistically significant, an increase in the amount of 
positive DOTAP used and the inclusion of the fusogenic lipid DOPE appeared to result in 
a trend to decreased TS mRNA levels (Figure 3.18A) suggesting that increasing their use 
could potentially further decrease target mRNA levels. This would not be surprising, as 
an increase in DOTAP has been shown to increase liposomal uptake efficiency
165
. As 
utilized in other studies a way to test whether the issue is, in fact, a lack of endosomal 
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release, may be by incubation with influenza-derived fusogenic peptide diNF-7
166
 or 
exposure of siRNA:liposome preparations to cells in conjunction with photochemical 
internalization (PCI)
163
, both of which are proven methods to facilitate endosomal 
release. diNF-7 undergoes a conformational change at lower pHs due to protonation and 
the resulting complex fuses with endosomes, thus facilitating their destabilization. PCI 
relies on photosensitizer molecules that accumulate in endosomes and become activated 
upon exposure to blue light, whereby they produce singlet oxygen species that bind the 
membrane and increase its permeability
167
.  If, however, these have no effect, then the 
problem may arise from other causes, such as siRNA degradation once following cell 
internalization or a lack of liposome-siRNA release preventing proper RISC 
incorporation even if they are able to escape the endosome.  The first problem could be 
tested by first conjugating siRNA with biotin and then following a 24 h transfection 
isolating the biotin-siRNA using streptavidin beads
168
 and re-transfect them using a 
proven commercial agent (Lipofectamine) to determine if they are still functional.  The 
second potential issue could be investigated indirectly by incubating liposome-siRNA 
complexes in serum or various pH buffered solutions and measuring changes in free 
siRNA, by RiboGreen, for example
169
.  If no siRNA is being released, perhaps the 
liposomes are too stable and unable to efficiently release their payload.   
   The non-targeting and folate-decorated liposomes were characterized according 
to their surface charge, size, stability and ability to protect siRNA against nuclease 
degradation. Quantification of the amount of siRNA encapsulated is insufficiently precise 
and continues to require refinement.  Some strategies to achieve more accurate readings 
could include adding a highly anionic molecule (i.e. heparin) to outcompete siRNA for 
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lipid/protamine binding so it can freely bind the RiboGreen dye, or, modify RNA 
isolation kits that utilize filter/ultracentrifuge techniques to concentrate siRNA
170
. 
Enhanced uptake of folate-decorated liposomes compared to their non-targeting 
counterparts in FR positive human cells was achieved by increasing the amount of folate 
inserted into their outer leaflet over a shortened time of exposure of siRNA:liposomal 
constructs to target cells. Unfortunately, downregulation of TS mRNA levels using TS 
siRNA:liposome preparations was not achieved in spite of preferential uptake by FR-
positive cells. However, the data suggest possible causes of lack of effectiveness of 
siRNA delivered using liposomal methods and areas for future study. 
This work required a great deal of troubleshooting especially in the early stages to 
achieve enhanced delivery of folate decorated liposomes to FR positive cancer cells 
compared with non-targeting particles. Keeping this in consideration, the enhanced 
uptake with our folate decorated liposome may not have been as great as reported in 
some of the literature
144,155
, however, I would caution fellow researchers to consider the 
physiological relevance of the cell cultures commonly used.  The gold standard in the 
literature appears to be KB or cells synthetically transfected with high FR expressing 
vectors grown and maintained in folate depleted media
171,172
, which promotes FR 
upregulation and may indeed have rendered these cells far more addictive to folate than 
the physiological folate levels exposed to normal or malignant FR expressing cells
124
.  
Therefore, I think this work can be used to help bring the study of FR-mediated uptake to 
other FR expressing cancer types and the probable realistic gains that can be achieved.   
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